Organic molecules for optoelectronic devices

Abstract

The invention relates to (specifically, to) organic molecules. According to the invention, the organic molecule has multiple units, wherein each unit comprises or is composed of a structure represented by formula (IV): where m is an integer from 2 to 6; n = 0 or 1; and X is independently selected each time it appears from structures consisting of direct bonds, CR... 3 R 4 C = CR 3 R 4 C=O, C=NR 3 NR 3 O, SiR 3 R 4 The group consists of S, S(O) and S(O)2.

Description

TECHNICAL FIELD

[0001] The invention relates to organic molecules in the form of oligomers comprising at least two structural units and the use of organic molecules in organic light emitting diodes (OLEDs) and in other optoelectronic devices. BACKGROUND

[0002] The use of organic molecules in optoelectronic devices is under intense development. SUMMARY

[0003] It was an objective of the present invention to provide organic molecules suitable for use in optoelectronic devices.

[0004] This objective was achieved by the present invention which provides a novel class of organic molecules.

[0005] According to the invention, the organic molecules are purely organic molecules, i.e. the organic molecules do not contain any metal ions in contrast to known metal complexes used in optoelectronic devices.

[0006] According to the present invention, the organic molecules exhibit an emission maximum in the blue spectral range, in the sky blue spectral range or in the green spectral range. In particular, the organic molecules exhibit an emission maximum between 420 nm and 520 nm, preferably between 440 nm and 495 nm, more preferably between 450 nm and 470 nm, or in particular the organic molecules exhibit an emission maximum below 560 nm, more preferably below 550 nm, even more preferably below 545 nm, or even below 540 nm. The emission maximum will typically be above 500 nm, more preferably above 510 nm, even more preferably above 515 nm, or even above 520 nm. In particular, the photoluminescence quantum yield of the organic molecules according to the invention is 50% or more. The use of the organic molecules according to the invention in optoelectronic devices, such as organic light emitting diodes (OLEDs), leads to a higher efficiency or a higher color purity (expressed by the full width at half maximum (FWHM) of the emission) of the optoelectronic devices. The corresponding OLEDs have a higher stability than OLEDs with known emitter materials and comparable color.

[0007] The organic molecules (or called "organic light emitting molecules") (oligomers) of the invention comprise or consist of a structure of formula I:

[0008]

[0009] wherein,

[0010] n = 0 or 1 ;

[0011] X is at each occurrence independently from another selected from the group consisting of a direct bond, CR 3 R 4, C=CR 3 R 4 , C=O, C=NR 3 , NR 3 , O, SiR 3 R 4 , S, S(O) and S(O)2;

[0012] R 1 , R 2 , R 3 , R 4 , R I , R II , R III , R IV and R V are selected from the group consisting of hydrogen; deuterium; N(R 5 )2; OR 5 ; SR 5 ; Si(R 5 )3; B(OR 5 )2; B(R 5 )2; OSO2R 5 ; CF3; CN; halogen (e.g. F; Br; I); C1-C 40 alkyl, optionally substituted with one or more substituents R 5 , and wherein one or more CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 ; C1-C 40 alkoxy, optionally substituted with one or more substituents R 5 , and wherein one or more CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 ; C1-C40 Thioalkoxy groups, optionally substituted with one or more substituents R 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 P(=O)(R) 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C2-C 40 Alkenyl, optionally substituted with one or more substituents R 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 P(=O)(R) 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C2-C 40 The alkynyl group may optionally be substituted with one or more substituents R. 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 P(=O)(R) 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C6-C 60 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 57 Heteroaryl, optionally substituted with one or more substituents R 5 ;

[0013] R d and R eindependently from each other selected from the group consisting of hydrogen; deuterium; CF3; CN; F; Br; I; Ci-C4-alkyl, optionally substituted with one or more of the substituents R 40 alkyl, optionally substituted with one or more of the substituents R a , and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , CºC, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; C6-C 60 aryl, optionally substituted with one or more of the substituents R a ; and C2-C 57 heteroaryl, optionally substituted with one or more of the substituents R a ;

[0014] R a is at each occurrence independently selected from the group consisting of hydrogen; deuterium; N(R 5 )2; OR 5 ; SR 5 ; Si(R 5 )3; B(OR 5 )2; B(R 5 )2; OSO2R 5 ; CF3; CN; halogen (e.g. F; Br; I); Ci-C 40 alkyl, optionally substituted with one or more of the substituents R 5 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , CºC, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; Ci-C 40 alkoxy, optionally substituted with one or more of the substituents R 5 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 40 ; C1-C 5 thioalkoxy, optionally substituted with one or more substituents R 5 , and where one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 40 ; C2-C 5 alkenyl, optionally substituted with one or more substituents R 5 , and where one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 40 ; C2-C 5 alkynyl, optionally substituted with one or more substituents R 5 , and where one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 60 ; C6-Caryl, optionally substituted with one or more substituents R 5 ; and C2-C 57 heteroaryl, optionally substituted with one or more substituents R 5 ;

[0015] R 5 independently from each other at each occurrence are selected from the group consisting of: hydrogen; deuterium; N(R 6 )2; OR 6 ; Si(R 6 )3; B(OR 6 )2; B(R 6 )2; OSO2R 6 ; CF3; CN; F; Br; I; Ci-C 40 alkyl, optionally substituted with one or more substituents R 6 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 6 C=CR 6 , C≡C, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=0, C=S, C=Se, C=NR 6 , P(=0)(R 6 ), SO, S02, NR 6 , O, S or CONR 6 ; Ci-C 40 alkoxy, optionally substituted with one or more substituents R 6 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 6 C=CR 6 , C≡C, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=0, C=S, C=Se, C=NR 6 , P(=0)(R 6 ), SO, S02, NR 6 , O, S or CONR 6 ; Ci-C 40 thioalkoxy, optionally substituted with one or more substituents R 6 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 6 C=CR 6 , C≡C, Si(R 6 )2, Ge(R 6 )2, Sn(R 6)2, C=0, C=S, C=Se, C=NR 6 , P(=0)(R 6 ), SO, S02, NR 6 , O, S or CONR 6 substituted; C2-C 40 alkenyl, which is optionally substituted with one or more substituents R 6 , and where one or more non-adjacent CH2groups are optionally substituted by R 6 C=CR 6 , C≡C, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=0, C=S, C=Se, C=NR 6 , P(=0)(R 6 ), SO, S02, NR 6 , O, S or CONR 6 substituted; C2-C 40 alkynyl, which is optionally substituted with one or more substituents R 6 , and where one or more non-adjacent CH2groups are optionally substituted by R 6 C=CR 6 , C≡C, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=0, C=S, C=Se, C=NR 6 , P(=0)(R 6 ), SO, S02, NR 6 , O, S or CONR 6 substituted; C6-C 60 aryl, which is optionally substituted with one or more substituents R 6 ; and C2-C 57 heteroaryl, which is optionally substituted with one or more substituents R 6 ;

[0016] R 6independently of one another at each occurrence are selected from the group consisting of hydrogen; deuterium; OPh; CF3; CN; F; C1-C5 alkyl, wherein one or more hydrogen atoms are optionally independently of one another substituted by deuterium, CN, CF3or F; C1-C5 alkoxy, wherein one or more hydrogen atoms are optionally independently of one another substituted by deuterium, CN, CF3or F; C1-C5 thioalkoxy, wherein one or more hydrogen atoms are optionally independently of one another substituted by deuterium, CN, CF3or F; C2-C5 alkenyl, wherein one or more hydrogen atoms are optionally independently of one another substituted by deuterium, CN, CF3or F; C2-C5 alkynyl, wherein one or more hydrogen atoms are optionally independently of one another substituted by deuterium, CN, CF3or F; C6-C 18 aryl, optionally substituted by one or more C1-C5 alkyl substituents; C2-C 17 heteroaryl, optionally substituted by one or more C1-C5 alkyl substituents; N(C6-C 18 aryl)2; N(C2-C 17 heteroaryl)2; and N(C2-C 17 heteroaryl)(C6-C 18 aryl);

[0017] wherein the substituents R a , R d , R e and R 5 independently of one another optionally form a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R a , R d , R e and R 5 ;

[0018] wherein the substituents R 1 , R 2 , R 3 , R 4 , R 5 , R I , R II , R III , R IV and R V independently of one another optionally form a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 1 , R 2 , R 3 , R 4 , R 5 , R I , R II , R III , R IV and R Valiphatic, aromatic, heteroaromatic and / or benzo-fused ring systems, which are formed as single or multiple rings.

[0019] Examples of substituents R a , R d , R e , R 1 , R 2 , R 3 , R 4 , R 5 , R I , R II , R III , R IV and R V include C6-C 60 aryl (preferably C6-C 30 aryl, more preferably C6-C 18 aryl, even more preferably C6-C 10 aryl).

[0020] Specific aryl substituents include monocyclic benzene, bicyclic biphenyl, condensed bicyclic naphthalene, tricyclic terphenyl (m-terphenyl, o-terphenyl, p-terphenyl), condensed tricyclic systems (such as acenaphthene, fluorene, phenalene, phenanthrene), condensed tetracyclic systems (such as triphenylene (benzo[9,10]phenanthrene), pyrene, tetracene), condensed pentacyclic systems (such as chrysene and pentacene).

[0021] Examples of substituents R a , R d , R e , R 1 , R 2 , R 3 , R 4 , R 5 , R I , R II , R III , R IV and R V include C2-C 57 heteroaryl (preferably C2-C 30 heteroaryl, more preferably C2-C 17 heteroaryl, even more preferably C2-C 10 heteroaryl).

[0022] Specific heteroaryl substituents include pyrrole, oxazole, isoxazole, thiazole, isothiazole, imidazole, oxadiazole, thiadiazole, triazole, tetraazole, pyrazole, pyridine, pyrimidine, pyridazine, pyrazine, triazine, indole, isoindole, 1H-indazole, benzimidazole, benzoxazole, benzothiazole, 1H-benzotriazole, quinoline, isoquinoline, cyclophosphine, quinazoline, quinoxaline, phthalazine, naphthidine, purine, pteridine, carbazole, acridine, phenoxathiin, phenoxazine ring, phenthiazine, phenazine, furan, benzofuran, isobenzofuran, dibenzofuran, thiophene, benzothiophene, dibenzothiophene, furazine, oxadiazole, and thianthracene.

[0023] For substituent R a R d R e R 1 R 2 R 3 R 4 R 5 R I R II R III R IV and R V Examples include C1-C 40 Alkyl (preferably C1-C) 24 Alkyl, branched, or cyclic C3-C 40 Alkyl, more preferably C1-C 18 Alkyl, branched, or cyclic C3-C 18 Alkyl groups, or even more preferably C1-C 12 Alkyl, branched, or cyclic C3-C 12 Alkyl groups, even more preferably C1-C6 alkyl groups or branched or cyclic C3-C6 alkyl groups, particularly preferably C1-C4 alkyl groups or branched C3-C4 alkyl groups.

[0024] Specific alkyl substituents include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-hexyl, 1-methyl, pentyl, 4-methyl-2-pentyl, 3,3-dimethylbutyl, 2-ethylbutyl, n-heptyl, 1-methylhexyl, n-octyl, tert-octyl, 1-methylheptyl, 2-ethylhexyl, 2-propylpentyl, n-nonyl, cyclohexyl, 2,2-dimethylheptyl, 2,6-dimethyl-4-heptyl, 3,5,5-trimethylhexyl, n-decyl, n-undecyl, 1-methyldecyl, n-dodecyl, n-tridecyl, 1-hexylheptyl, n-tetradecyl, n-pentadecanyl, n-hexadecyl, n-heptadecyl, n-octadecyl, n-dodecyl, etc.

[0025] For substituent R a R dR e R 1 R 2 R 3 R 4 R 5 R I R II R III R IV and R V Examples include C1-C 40 Alkoxy (preferably C1-C) 24 alkoxy or branched or cyclic C3-C 40 Alkoxy, more preferably C1-C 18 alkoxy or branched or cyclic C3-C 18 Alkoxy groups, or even more preferably C1-C 12 alkoxy or branched or cyclic C3-C 12 Alkyl groups, even more preferably C1-C6 alkoxy groups or branched or cyclic C3-C6 alkoxy groups, particularly preferably C1-C4 alkoxy groups or branched C3-C4 alkoxy groups.

[0026] Specific alkoxy substituents include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy, hexoxy, heptoxy, octoxy, etc.

[0027] For substituent R a R d R e R 1 R 2 R 3 R 4 R 5 R I R II R III R IV and R V Examples include C1-C 40 Thioalkoxy (preferably C1-C) 24 Thioalkoxy or branched or cyclic C3-C 40 Thioalkoxy, more preferably C1-C 18 Thioalkoxy or branched or cyclic C3-C 18 Thioalkoxy, even preferably C1-C 12 Thioalkoxy or branched or cyclic C3-C 12 Thioalkoxy, even more preferably C1-C6 thioalkoxy or branched or cyclic C3-C6 thioalkoxy, particularly preferably C1-C4 thioalkoxy or branched C3-C4 thioalkoxy).

[0028] For substituent R a R d R e R 1 R 2 R 3 R 4 R 5 R I R II R III R IV and R V Examples include C2-C 40 alkenyl (preferably C2-C) 24 Alkenyl, branched, or cyclic C3-C 40 Alkenyl, more preferably C2-C 18 Alkenyl, branched, or cyclic C3-C 18 Alkenyl, or even more preferably C2-C 12 Alkenyl, branched, or cyclic C3-C 12 Alkenyl, even more preferably C2-C6 alkenyl or branched or cyclic C3-C6 alkenyl, particularly preferably C2-C4 alkenyl or branched C3-C4 alkenyl).

[0029] For substituent R a R d R e R 1 R 2 R 3 R 4 R 5 R I R II R III R IV and R V Examples include C2-C 40 alkynyl group (preferably C2-C) 24 Alkyne group or branched or cyclic C3-C 40 Alkyne group, more preferably C2-C 18 Alkyne group or branched or cyclic C3-C 18 Alkyne group, or even more preferably C2-C 12 Alkyne group or branched or cyclic C3-C 12 The alkynyl group, even more preferably C2-C6 alkynyl or branched or cyclic C3-C6 alkynyl, particularly preferably C2-C4 alkynyl or branched C3-C4 alkynyl.

[0030] In a preferred embodiment, R 1 R 2 R 3 R 4 RI , R II , R III , R IV and R V are independently from each other selected from the group consisting of hydrogen, deuterium, N(R 5 )2, OR 5 , SR 5 , Si(R 5 )3, B(OR 5 )2, B(R 5 )2, OSO2R 5 , CF3, CN, halogen, C1-C 18 alkyl, which is optionally substituted with one or more substituents R 5 , and wherein one or more CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 ; C1-C 18 alkoxy, which is optionally substituted with one or more substituents R 5 , and wherein one or more CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 ; C1-C 18 thioalkoxy, which is optionally substituted with one or more substituents R 5 , and wherein one or more CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5SO2, NR 5 O, S or CONR 5 substituted; C2-C 18 alkenyl, which is optionally substituted with one or more substituents R 5 and where one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, SO2, NR 5 O, S or CONR 5 substituted; C2-C 18 alkynyl, which is optionally substituted with one or more substituents R 5 and where one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, SO2, NR 5 O, S or CONR 5 substituted; C6-C 18 aryl, which is optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, which is optionally substituted with one or more substituents R 5 .

[0031] R 5 is at each occurrence and independently from occurrence to occurrence selected from the group consisting of: hydrogen; deuterium; N(R 6 )2; OR 6 ; Si(R 6 )3; B(OR 6 )2; B(R 6 )2; OSO2R 6 ; CF3; CN; F; Br; I; Ci-C 18 alkyl, which is optionally substituted with one or more substituents R 6 and where one or more non-adjacent CH2groups are optionally substituted by R 6 C=CR 6 , C≡C, Si(R6 )2、Ge(R 6 )2、Sn(R 6 )2. C=O, C=S, C=Se, C=NR 6 、P(=O)(R 6 SO, SO2, NR 6 O, S or CONR 6 Replacement; C1-C 18 Alkoxy, optionally substituted with one or more substituents R 6 And wherein, one or more non-adjacent CH2 groups are optionally R 6 C = CR 6 C≡C, Si(R) 6 )2、Ge(R 6 )2、Sn(R 6 )2. C=O, C=S, C=Se, C=NR 6 、P(=O)(R 6 SO, SO2, NR 6 O, S or CONR 6 Replacement; C1-C 18 Thioalkoxy groups, optionally substituted with one or more substituents R 6 And wherein, one or more non-adjacent CH2 groups are optionally R 6 C = CR 6 C≡C, Si(R) 6 )2、Ge(R 6 )2、Sn(R 6 )2. C=O, C=S, C=Se, C=NR 6 、P(=O)(R 6 SO, SO2, NR 6 O, S or CONR 6 Replacement; C2-C 18 Alkenyl, optionally substituted with one or more substituents R 6 And wherein, one or more non-adjacent CH2 groups are optionally R 6 C = CR 6 C≡C, Si(R) 6 )2、Ge(R 6 )2、Sn(R 6 )2. C=O, C=S, C=Se, C=NR 6 、P(=O)(R 6 SO, SO2, NR 6 O, S or CONR 6 Replacement; C2-C 18The alkynyl group may optionally be substituted with one or more substituents R. 6 And wherein, one or more non-adjacent CH2 groups are optionally R 6 C = CR 6 C≡C, Si(R) 6 )2、Ge(R 6 )2、Sn(R 6 )2. C=O, C=S, C=Se, C=NR 6 、P(=O)(R 6 SO, SO2, NR 6 O, S or CONR 6 Replacement; C6-C 18 aryl, optionally substituted with one or more substituents R 6 ; and C2-C 17 Heteroaryl, optionally substituted with one or more substituents R 6 .

[0032] In a preferred embodiment, n = 1.

[0033] In another embodiment, n = 0.

[0034] In a preferred embodiment, R 1 R 2 R 3 R 4 R I R II R III R IV and R V They are selected independently from the group consisting of: hydrogen; deuterium; N(R) 5 )2; OR 5 ;Si(R) 5 )3;B(R 5 )2; CF3; CN; Halogen; C1-C 18 Alkyl groups, optionally substituted with one or more substituents R 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 、P(=O)(R 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C6-C 18aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 Heteroaryl, optionally substituted with one or more substituents R 5 ;and

[0035] R 5 Each time it appears, it is independently selected from the group consisting of: hydrogen; deuterium; N(R) 6 )2; OR 6 ;Si(R) 6 )3;B(R 6 )2;CF3;CN;F;Br;I;C1-C 18 Alkyl groups, optionally substituted with one or more substituents R 6 And wherein one or more non-adjacent CH2 groups are optionally R 6 C = CR 6 C≡C, Si(R) 6 )2、Ge(R 6 )2、Sn(R 6 )2. C=O, C=S, C=Se, C=NR 6 、P(=O)(R 6 SO, SO2, NR 6 O, S or CONR 6 Replacement; C6-C 18 aryl, optionally substituted with one or more substituents R 6 ; and C2-C 17 Heteroaryl, optionally substituted with one or more substituents R 6 .

[0036] In a preferred embodiment, R 1 R 2 R 3 R 4 R I R II R III R IV and R V They are independently selected from the group consisting of: hydrogen; deuterium; N(R) 5 )2; OR 5 ;Si(R) 5 )3;B(R 5 )2; CF3; CN; Halogen; C1-C 18 Alkyl groups, optionally substituted with one or more substituents R 5 And wherein one or more non-adjacent CH2 groups are optionally R 5 C = CR 5C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 P(=O)(R) 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 Heteroaryl, optionally substituted with one or more substituents R 5 ;and

[0037] R 5 Each time it appears, it is independently selected from the group consisting of: hydrogen; deuterium; N(R) 6 )2; OR 6 ;Si(R) 6 )3;B(R 6 )2;CF3;CN;F;Br;I;C1-C 18 Alkyl groups, optionally substituted with one or more substituents R 6 And wherein, one or more non-adjacent CH2 groups are optionally R 6 C = CR 6 C≡C, Si(R) 6 )2、Ge(R 6 )2、Sn(R 6 )2. C=O, C=S, C=Se, C=NR 6 P(=O)(R) 6 SO, SO2, NR 6 O, S or CONR 6 Replacement; C6-C 18 aryl, optionally substituted with one or more substituents R 6 ; and C2-C 17 Heteroaryl, optionally substituted with one or more substituents R 6 ,

[0038] Among them, group R 1 R 2 R 3 R 4 R I R II R III R IV R 5 and R VThey may optionally combine with each other to form an aromatic or heteroaromatic ring that may optionally be substituted with one or more C1-C5 alkyl substituents, deuterium, halogen, CN, or CF3.

[0039] In a preferred embodiment, R 1 R 2 R 3 R 4 R I R II R III R IV and R V They are selected independently from the group consisting of: hydrogen; deuterium; N(R) 5 )2; OR 5 ;Si(R) 5 )3;B(R 5 )2; CF3; CN; Halogen; C1-C 18 Alkyl groups, optionally substituted with one or more substituents R 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 P(=O)(R) 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 Heteroaryl, optionally substituted with one or more substituents R 5 ;and

[0040] R 5 Each time it appears, it is independently selected from the group consisting of: hydrogen; deuterium; N(R) 6 )2; OR 6 ;Si(R) 6 )3;B(R 6 )2;CF3;CN;F;Br;I;C1-C 18 Alkyl groups, optionally substituted with one or more substituents R 6 And wherein, one or more non-adjacent CH2 groups are optionally R 6 C = CR 6 C≡C, Si(R) 6 )2、Ge(R 6)2, Sn(R 6 )2, C=0, C=S, C=Se, C=NR 6 , P(=0)(R 6 ), SO, S02, NR 6 , O, S or CONR 6 substituted; C6-C 18 aryl, optionally substituted with one or more substituents R 6 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 6 ,

[0041] wherein groups R 1 , R 2 , R I , R II , R III , R IV , R 5 and R V are optionally bound to each other to form an aromatic or heteroaromatic ring, optionally substituted with one or more C1-C5 alkyl substituents, deuterium, halogen, CN or CF3.

[0042] In preferred embodiments, R 1 , R 2 , R 3 , R 4 , R I , R II , R III , R IV and R V are independently from each other selected from the group consisting of hydrogen; deuterium; N(R 5 )2; OR 5 ; Si(R 5 )3; B(R 5 )2; CF3; CN; halogen; C1-C 18 alkyl, optionally substituted with one or more substituents R 5 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 substituted; C6-C 18C6-C10aryl, optionally substituted with one or more substituents R 5 ; and C2-C10heteroaryl, optionally substituted with one or more substituents R 17 ; and C2-C10heteroaryl, optionally substituted with one or more substituents R 5 ; and

[0043] R 5 is at each occurrence independently selected from the group consisting of: hydrogen; deuterium; N(R 6 )2; OR 6 ; Si(R 6 )3; B(R 6 )2; CF3; CN; F; Br; I; Ci-C6alkyl, optionally substituted with one or more substituents R 18 ; and wherein one or more non-adjacent CH2groups are optionally substituted with R 6 C=CR 6 , CºC, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=0, C=S, C=Se, C=NR 6 , P(=0)(R 6 ), SO, S02, NR 6 , O, S or CONR 6 ; C6-Cioaryl, optionally substituted with one or more substituents R 6 ; and C2-C10heteroaryl, optionally substituted with one or more substituents R 18 .

[0044] In one embodiment, R 6 , R 17 , R 6 , R 1 , R 2 , R 3 , R 4 , R I , R II , R III , R IV and R V are independently from each other selected from the group consisting of: hydrogen; deuterium; Ci-C6alkyl, optionally substituted with one or more substituents R 18 ; and wherein one or more non-adjacent CH2groups are optionally substituted with R 5 C=CR 5 , CºC, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 )., P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 substituted; C6-C 18 aryl, which is optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, which is optionally substituted with one or more substituents R 5 .

[0045] In one embodiment, R 1 , R 2 , R I , R II , R III , R IV and R V are independently from each other selected from the group consisting of hydrogen; deuterium; C1-C 18 alkyl, which is optionally substituted with one or more substituents R 5 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 substituted; C6-C 18 aryl, which is optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, which is optionally substituted with one or more substituents R 5 ;

[0046] wherein groups R 1 , R 2 , R I , R II , R III , R IV and R V which are located next to each other are optionally bound to each other to form an aromatic or heteroaromatic ring which is optionally substituted with one or more C1-C5alkyl substituents, deuterium, halogen, CN or CF3.

[0047] In one embodiment, R 3 and R 4 are independently from each other selected from the group consisting of C1-C 18alkyl, which is optionally substituted with one or more substituents R 5 and wherein one or more non-adjacent Chb groups are optionally substituted by R 5 C=CR 5 , CºC, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; C6-C 18 aryl, which is optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, which is optionally substituted with one or more substituents R 5 .

[0048] In one embodiment, R 1 , R 2 , R 3 , R 4 , R I , R II , R III , R IV and R V are independently from each other selected from the group consisting of C1-C 18 alkyl, which is optionally substituted with one or more substituents R 5 and wherein one or more non-adjacent Chb groups are optionally substituted by R 5 C=CR 5 , CºC, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; C6-C 18 aryl, which is optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, which is optionally substituted with one or more substituents R 5 .

[0049] In another embodiment, R 1 , R 2 , R 3 , R4 R I R II R III R IV and R V are independently of each other selected from the group consisting of C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 .

[0050] In another embodiment, R 1 R 2 R 3 R 4 R I R II R III R IV and R V are independently of each other selected from the group consisting of C6-C 18 aryl, optionally substituted with one or more substituents R 5 .

[0051] In a preferred embodiment, R 3 are independently of each other selected from the group consisting of C1-C 40 alkyl, optionally substituted with one or more substituents R 5 ; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 .

[0052] In a preferred embodiment, R 3 are independently of each other selected from the group consisting of C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 .

[0053] In a more preferred embodiment, R 3 are independently of each other selected from the group consisting of C6-C 18 aryl, optionally substituted with one or more substituents R 5 .

[0054] In a more preferred embodiment, R 3is optionally substituted with one or more substituents R 6 C6-C 18 aryl.

[0055] In a more preferred embodiment, R 3 is phenyl (Ph) optionally substituted with one or more substituents R 5 .

[0056] In a particular embodiment, R 3 is phenyl (Ph) optionally substituted with one or more substituents R 6 .

[0057] In a particular embodiment, R 3 is phenyl (Ph) optionally substituted with one or more C1-C5 alkyl substituents.

[0058] In a particular embodiment, R 3 is phenyl (Ph) optionally substituted with one or more of the following substituents, independently of one another: C1-C5 alkyl, wherein one or more hydrogen atoms are optionally substituted, independently of one another, with deuterium, CN, CF3 or F; C6-C 18 aryl, optionally substituted with one or more C1-C5 alkyl substituents; and C2-C 17 heteroaryl, optionally substituted with one or more C1-C5 alkyl substituents.

[0059] In a particular embodiment, R 3 is Ph.

[0060] In one embodiment, R 1 , R 2 , R 3 , R 4 , R I , R II , R III , R IV and R V are selected, independently of one another, from the group consisting of C1-C 18 alkyl, optionally substituted with one or more substituents R 5 , and wherein one or more non-adjacent CH2 groups are optionally substituted with R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5O, S or CONR 5 substituted.

[0061] In one embodiment, at least one substituent selected from the group consisting of R 1 , R 2 , R I , R II , R III , R IV , R V and R a is: C1-C 18 alkyl, optionally substituted with one or more substituents R 5 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , CºC, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 substituted.

[0062] In one embodiment, at least one substituent selected from the group consisting of R 1 , R 2 , R I , R II , R III , R IV , R V and R a is: Me; i Pr; and t Bu.

[0063] In one embodiment, R a is at each occurrence independently of each other selected from the group consisting of: hydrogen; deuterium; C1-C 18 alkyl, optionally substituted with one or more substituents R 5 ; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 .

[0064] In one embodiment, R a is at each occurrence independently of each other selected from the group consisting of: hydrogen; deuterium; C1-C 18alkyl, optionally substituted with one or more substituents R 5 ; and C6-C 18 aryl, optionally substituted with one or more substituents R 5 .

[0065] In one embodiment, R a is, at each occurrence, independently selected from the group consisting of hydrogen; deuterium; and C1-C 18 alkyl, optionally substituted with one or more substituents R 5 .

[0066] In one embodiment, at least one R a is Me; i Pr; or t Bu.

[0067] In a preferred embodiment, at least one substituent selected from the group consisting of R 1 , R 2 , R I , R II , R III , R IV , and R V forms a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 1 , R 2 , R 3 , R 4 , R 5 , R I , R II , R III , R IV , and R V .

[0068] In a more preferred embodiment, at least one substituent selected from the group consisting of R 1 , R 2 , R I , R II , R III , R IV , and R V forms an aromatic and / or heteroaromatic benzo-fused ring system with one or more substituents R 1 , R 2 , R 3 , R 4 , R 5 , R I , R II , R III , R IV , and R V .

[0069] In a more preferred embodiment, the material is selected from R 1 R 2 R I R II R III R IV and R V At least one substituent in the group consists of one or more adjacent substituents R. 1 R 2 R I R II R III R IV and R V Formation of aromatic and / or heteroaromatic benzo[a] fused ring systems.

[0070] R 1 Positioned as R I Adjacent; R I Positioned as R II and R 1 Adjacent, R II Positioned as R III and R I Adjacent; R III Positioned as R II Adjacent, R 2 Positioned as R V Adjacent, R V Positioned as R 2 and R IV Adjacent, and R IV Positioned as R V Adjacent.

[0071] In a more preferred embodiment, the material is selected from R 1 R 2 R I R II R III R IV and R V At least one substituent in the group consists of one or more adjacent substituents R. 1 R 2 R I R II R III R IV and R V Forming monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo[a] fused ring systems.

[0072] R 1 Positioned as R I Adjacent; R I Positioned as R II and R1 adjacent to R II is positioned adjacent to R III and R I is positioned adjacent to R III is positioned adjacent to R II is positioned adjacent to R 2 is positioned adjacent to R V is positioned adjacent to R V is positioned adjacent to R 2 and R IV is positioned adjacent to R IV is positioned adjacent to R V .

[0073] In preferred embodiments, at least one substituent selected from the group consisting of R 1 , R 2 , R I , R II , R III , R IV and R V forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 1 , R 2 , R 3 , R 4 , R 5 , R I , R II , R III , R IV and R V , wherein the ring system is selected from the following groups:

[0074]

[0075] wherein each dotted line is a point of attachment.

[0076] In preferred embodiments, at least one substituent selected from the group consisting of R 1 , R 2 , R I , R II , R III , R IV and R V forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 1 , R 2 , R 3 , R 4 , R 5 , R I , R II , R III , R IV and R Vforming a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system, wherein the ring system is selected from the group consisting of:

[0077]

[0078] wherein each dotted line is a connection point.

[0079] In a preferred embodiment, the connection points are positioned adjacent to each other. This means that R 1 preferably forms a ring system with R I I preferably forms a ring system with R II and / or R 1 II preferably forms a ring system with R III and / or R I III preferably forms a ring system with R II 2 preferably forms a ring system with R V V preferably forms a ring system with R 2 and / or R IV IV preferably forms a ring system with R V

[0080] In the following specific examples are listed:

[0081]

[0082] In one embodiment, at least one substituent selected from the group consisting of R 1 , R 2 , R I , R II , R III , R IV and R V forms a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 1 , R 2 , R I , R II , R III , R IV and R V , wherein the ring system is selected from the group consisting of:

[0083]

[0084] wherein X 1 is S, O or NR 5 . ​​​​​​​

[0085] In a preferred embodiment, the connection points are positioned as adjacent to each other.

[0086] In another embodiment, selected from R 1 R I R II and R III At least one substituent in the group consists of one or more substituents R 1 R I R II and R III Forming monocyclic or polycyclic aliphatic, aromatic, heteroaromatic, and / or benzo[a]-fused ring systems, wherein the ring system is selected from the group consisting of:

[0087]

[0088] Each dashed line represents a connection point.

[0089] In another embodiment, selected from R 1 R I R II and R III At least one substituent in the group consists of one or more substituents R 1 R I R II and R III Forming monocyclic or polycyclic aliphatic, aromatic, heteroaromatic, and / or benzo[a]-fused ring systems, wherein the ring system is selected from the group consisting of:

[0090]

[0091] Each dashed line represents a connection point.

[0092] In a preferred embodiment, the connection points are positioned adjacent to each other. This means R 1 Preferably with R I Forming a ring system; R I Preferably with R II and / or R 1 Forming a ring system; R II Preferably with R III and / or R I Forming a ring system; and R III Preferably with R II Forming a ring system.

[0093] In one embodiment, selected from R 1 R 2 R I R II R III R IV and RV at least one substituent from the group consisting of R 1 , R 2 , R I , R II , R III , R IV and R V form a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system, wherein the ring system is selected from the group consisting of

[0094]

[0095] wherein X 2 is N or CR 5 ;

[0096] wherein X 3 is N or CR 5 .

[0097] In preferred embodiments, the connection points are positioned adjacent to each other.

[0098] In preferred embodiments, R d and R e are at each occurrence independently selected from the group consisting of hydrogen; deuterium; CF3; CN; F; Br; I; Ci-C 18 alkyl, optionally substituted with one or more substituents R a , and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , CºC, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; C6-C 18 aryl, optionally substituted with one or more substituents R a ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R a .

[0099] In preferred embodiments, R a is at each occurrence independently from each other selected from the group consisting of hydrogen; deuterium; N(R 5 )2; OR 5 ; SR 5 ; Si(R5 )3; B(OR 5 )2; B(R 5 )2; OSO2R 5 ; CF3; CN; halogen; Ci-C 18 alkyl, optionally substituted with one or more substituents R 5 , and where one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; Ci-C 18 alkoxy, optionally substituted with one or more substituents R 5 , and where one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; C2-C 18 thioalkoxy, optionally substituted with one or more substituents R 5 , and where one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; C2-C 18 alkenyl, optionally substituted with one or more substituents R 5 , and where one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 、P(=O)(R 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C2-C 18 The alkynyl group may optionally be substituted with one or more substituents R. 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 、P(=O)(R 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 Heteroaryl, optionally substituted with one or more substituents R 5 .

[0100] In one embodiment, at least one R a Unlike hydrogen.

[0101] In one embodiment, R a Each time it appears, it is independently selected from the group consisting of: hydrogen; deuterium; N(R) 5 )2; C1-C 18 Alkyl groups, optionally substituted with one or more substituents R 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 、P(=O)(R 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C6-C 18 aryl, optionally substituted with one or more substituents R5 ; and C2-C 17 Heteroaryl, optionally substituted with one or more substituents R 5 , or R a With one or more substituents R a and R 5 Forming monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo[a] fused ring systems.

[0102] In one embodiment, R a Each time it appears, it is independently selected from the group consisting of: hydrogen; deuterium; N(R) 5 )2; C1-C 18 Alkyl groups, optionally substituted with one or more substituents R 5 And wherein one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 、P(=O)(R 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 Heteroaryl, optionally substituted with one or more substituents R 5 , or R a With one or more substituents R a and R 5 It forms a ring system of aromatic or heteroaromatic compounds.

[0103] In one embodiment of the invention, R a Each time it appears, it is independently selected from the group consisting of: hydrogen; Me; i Pr; t Bu; CN; CF3; F; aryl, optionally substituted with one or more substituents, said substituents being independently selected from Me, i Pr, t The group consisting of Bu, CN, CF3, F, and Ph; pyridyl, optionally substituted with one or more substituents, said substituents being independently selected from the group consisting of Me, i Pr, tBu, CN, CF3, F and Ph; triazinyl, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t Bu, CN, CF3, F and Ph; triazinyl, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t Bu, CN, CF3, F and Ph; triazinyl, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t Bu, F and Ph,

[0104] wherein the groups R a optionally bound to one another to form an aromatic or heteroaromatic ring optionally substituted with one or more C1-C5alkyl substituents, C6-C 18 aryl substituents, deuterium, halogen, CN or CF3.

[0105] In one embodiment of the invention, R a is independently at each occurrence selected from the group consisting of hydrogen; Me; i Pr; t Bu; CN; CF3; F; aryl, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t Bu, CN, CF3, F and Ph; triazinyl, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t Bu, CN, CF3, F and Ph; triazinyl, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t Bu, CN, CF3, F and Ph; triazinyl, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t Bu, CN, CF3, F and Ph; triazinyl, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t Bu, F and Ph.

[0106] In yet another embodiment of the invention, R aindependently at each occurrence, are selected from the group consisting of hydrogen; Me; i Pr; t Bu; F; Ph, optionally substituted with one or more substituents independently selected from the group consisting of Me, i Pr, t Bu, CN, CF3, F and Ph; carbazolyl, optionally substituted with one or more substituents independently selected from the group consisting of Me, i Pr, t Bu, CN, CF3, F and Ph; and N(Ph)2, optionally substituted with one or more substituents independently selected from the group consisting of Me, i Pr, t Bu, F and Ph.

[0107] independently at each occurrence, are selected from the group consisting of hydrogen; Me; a independently at each occurrence, are selected from the group consisting of hydrogen; Me; i Pr; t Bu; F; Ph, optionally substituted with one or more substituents independently selected from the group consisting of Me, i Pr, t Bu, CN, CF3, F and Ph; carbazolyl, optionally substituted with one or more substituents independently selected from the group consisting of Me, i Pr, t Bu, CN, CF3, F and Ph; and N(Ph)2, optionally substituted with one or more substituents independently selected from the group consisting of Me, i Pr, t Bu, F and Ph,

[0108] wherein groups R a optionally combine with each other to form an aromatic or heteroaromatic ring optionally substituted with one or more C1-C5alkyl substituents, C6-C 18 aryl substituents, deuterium, halogen, CN or CF3.

[0109] independently at each occurrence, are selected from the group consisting of hydrogen; Me; a independently at each occurrence, are selected from the group consisting of hydrogen; Me; i Pr; t Bu; F; Ph, optionally substituted with one or more substituents independently selected from the group consisting of Me, i Pr, tthe group consisting of Me, Et, i-Pr, n-Bu, i-Bu, t-Bu, Ph, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, Et, i-Pr, n-Bu, i-Bu, t-Bu, Ph, and N(Ph)2, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, Et, i-Pr, n-Bu, i-Bu, t-Bu, Ph, and N(Ph)2. i Pr, t the group consisting of Me, Et, i-Pr, n-Bu, i-Bu, t-Bu, Ph, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, Et, i-Pr, n-Bu, i-Bu, t-Bu, Ph, and N(Ph)2, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, Et, i-Pr, n-Bu, i-Bu, t-Bu, Ph, and N(Ph)2. i Pr, t the group consisting of Me, Et, i-Pr, n-Bu, i-Bu, t-Bu, Ph, and N(Ph)2.

[0110] independently at each occurrence selected from the group consisting of hydrogen; Me; a independently at each occurrence selected from the group consisting of hydrogen; Me; i Pr; t Bu; Ph, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t the group consisting of Me, Et, i-Pr, n-Bu, i-Bu, t-Bu, Ph, and N(Ph)2. i Pr, t the group consisting of Me, Et, i-Pr, n-Bu, i-Bu, t-Bu, Ph, and N(Ph)2. i Pr, t the group consisting of Me, Et, i-Pr, n-Bu, i-Bu, t-Bu, Ph, and N(Ph)2.

[0111] independently at each occurrence selected from the group consisting of hydrogen; Me; a independently at each occurrence selected from the group consisting of hydrogen; Me; i Pr; t Bu; Ph, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t the group consisting of Me, Et, i-Pr, n-Bu, i-Bu, t-Bu, Ph, and N(Ph)2. i Pr, t the group consisting of Me, Et, i-Pr, n-Bu, i-Bu, t-Bu, Ph, and N(Ph)2.

[0112] independently at each occurrence selected from the group consisting of hydrogen; Me; a independently at each occurrence selected from the group consisting of hydrogen; Me; i Pr; t Bu; and Ph, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t the group consisting of Me, Et, i-Pr, n-Bu, i-Bu, t-Bu, and Ph.

[0113] independently at each occurrence selected from the group consisting of hydrogen; Me;a Each time it appears, it is independently selected from the group consisting of: hydrogen; deuterium; N(R) 5 )2; C1-C 18 Alkyl groups, optionally substituted with one or more substituents R 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 P(=O)(R) 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 Heteroaryl, optionally substituted with one or more substituents R 5 , or R a With one or more substituents R a and R 5 Forming monocyclic or polycyclic aliphatic, aromatic, heteroaromatic, and / or benzo[a]-fused ring systems, wherein the ring system is selected from the group consisting of:

[0114]

[0115] Each dashed line represents a connection point.

[0116] In one embodiment, R a Each time it appears, it is independently selected from the group consisting of: hydrogen; deuterium; N(R) 5 )2; C1-C 18 Alkyl groups, optionally substituted with one or more substituents R 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 P(=O)(R) 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C6-C 18aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 , or R a and one or more substituents R a and R 5 form a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system, wherein the ring system is selected from the group consisting of

[0117]

[0118] wherein each dotted line is a connection point.

[0119] In a preferred embodiment, the connection points are positioned adjacent to each other. This means that R a is preferably positioned adjacent to each other with R a forming a ring system.

[0120] In the following specific examples are listed:

[0121]

[0122]

[0123]

[0124] In one embodiment, at least one R a and one or more substituents R a and R 5 form a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system, wherein the ring system is selected from the group consisting of

[0125]

[0126] wherein X 1 is S, O or NR 5 .

[0127] In a preferred embodiment, the connection points are positioned adjacent to each other.

[0128] In a preferred embodiment, the inventive organic light emitting molecule comprises or consists of a structure of formula I, and with the proviso that if X is NR 3 and R d and R e are connected to each other to form an aromatic ring system, then R V is N(R 5 )2 or with one or more substituents R 2 , R 3R 5 R IV form a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system.

[0129] In the following specific examples are listed:

[0130]

[0131] In preferred embodiments, the inventive organic light emitting molecule comprises or consists of a structure of formula I, and with the proviso that if X is NR 3 R d and R e are connected to each other to form an aromatic ring system, then R V is selected from N(R 6 )2or forms a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0132] In preferred embodiments, the inventive organic light emitting molecule comprises or consists of a structure of formula I, and with the proviso that if X is NR 3 R d and R e are connected to each other to form an aromatic ring system, then R V is selected from N(R 5 )2or forms a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more adjacent substituents R 2 and R IV .

[0133] In preferred embodiments, the inventive organic light emitting molecule comprises or consists of a structure of formula I, and with the proviso that if X is NR 3 R d and R e are connected to each other to form an aromatic ring system, then R V is selected from N(R 6 )2or forms a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more adjacent substituents R 2 and R IV .

[0134] In preferred embodiments, the inventive organic light emitting molecule comprises or consists of a structure of formula I, and with the proviso that if X is NR 3 R d and Re are connected to each other to form an aromatic ring system, then R V is N(R 5 )2.

[0135] In a preferred embodiment, the inventive organic light emitting molecule comprises or consists of a structure of formula I, and with the proviso that if X is NR 3 and R d and R e are connected to each other to form an aromatic ring system, then R V is N(R 6 )2.

[0136] In another preferred embodiment, the inventive organic light emitting molecule comprises or consists of a structure of formula I, and with the proviso that if X is NR 3 and R d and R e are connected to each other to form an aromatic ring system, then R V forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0137] In a more preferred embodiment, the inventive organic light emitting molecule comprises or consists of a structure of formula I, and with the proviso that if X is NR 3 and R d and R e are connected to each other to form an aromatic ring system, then R V forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more adjacent substituents R 2 and / or R IV .

[0138] Examples for n=0 and n=1 with different substituents X are shown below:

[0139]

[0140]

[0141] Additional examples of inventive organic molecules include:

[0142]

[0143] In a preferred embodiment, X is at each occurrence independently of each other selected from the group consisting of a direct bond, NR 3 , CR 3 R4 the group consisting of H, Me, Ph, CN, CF3, and N(Ph)2.

[0144] In a more preferred embodiment, X is at each occurrence independently of each other selected from the group consisting of a direct bond, NR 3 the group consisting of H, Me, Ph, CN, CF3, and N(Ph)2.

[0145] In a particular embodiment, X is at each occurrence independently of each other selected from the group consisting of a direct bond and NR 3 the group consisting of H, Me, Ph, CN, CF3, and N(Ph)2.

[0146] In one embodiment of the application, R 1 , R 2 , R 3 , R 4 , R I , R II , R III , R IV and R V are at each occurrence independently of each other selected from the group consisting of H; Me; i Pr; t Bu; CN; CF3; Ph, optionally substituted with one or more substituents independently of each other selected from the group consisting of Me, i Pr, t Bu, CN, CF3, and Ph; pyridyl, optionally substituted with one or more substituents independently of each other selected from the group consisting of Me, i Pr, t Bu, CN, CF3, and Ph; pyrimidinyl, optionally substituted with one or more substituents independently of each other selected from the group consisting of Me, i Pr, t Bu, CN, CF3, and Ph; carbazolyl, optionally substituted with one or more substituents independently of each other selected from the group consisting of Me, i Pr, t Bu, CN, CF3, and Ph; triazinyl, optionally substituted with one or more substituents independently of each other selected from the group consisting of Me, i Pr, t Bu, CN, CF3, and Ph; and N(Ph)2.

[0147] In one embodiment of the application, the organic molecules comprise or consist of a structure of Formula II:

[0148]

[0149] In a preferred embodiment of the application, X is at each occurrence independently of each other selected from the group consisting of a direct bond, NR3 A group consisting of O and .

[0150] In a preferred embodiment, the organic light-emitting molecule of the invention comprises or is composed of the structure of Formula II, provided that X is NR. 3 And R d and R e If they connect to form an aromatic ring system, then R V Selected from N(R) 5 )2 or with one or more substituents R 2 R 3 R 5 and R IV Forming monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo[a] fused ring systems.

[0151] In a preferred embodiment, the organic light-emitting molecule of the invention comprises or is composed of the structure of Formula II, provided that X is NR. 3 And R d and R e If they connect to form an aromatic ring system, then R V Selected from N(R) 5 )2 or with one or more adjacent substituents R 2 and / or R IV Forming monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo[a] fused ring systems.

[0152] In one embodiment of the invention, the organic molecule comprises or is composed of a structure of formula II-1:

[0153]

[0154] Among them, R 3 Selected from the group consisting of: C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 57 Heteroaryl, optionally substituted with one or more substituents R 5 .

[0155] In one embodiment of the invention, the organic molecule comprises or is composed of a structure of formula II-1, wherein R 3 Selected from the group consisting of: C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 57 Heteroaryl, optionally substituted with one or more substituents R 5 .

[0156] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula II-1, wherein R 3 is C6-C 5 aryl which is optionally substituted with one or more substituents R 18 .

[0157] In another embodiment of the application, the organic molecules comprise or consist of a structure of Formula II-1, wherein R 3 is C6-C 6 aryl which is optionally substituted with one or more substituents R 18 .

[0158] In a preferred embodiment, the organic molecules of the present application comprise or consist of a structure of Formula II-1, with the proviso that if R d and R e are attached to each other to form an aromatic ring system, then R V is selected from N(R 5 )2 or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0159] In a preferred embodiment, the organic molecules of the present application comprise or consist of a structure of Formula II-1, with the proviso that if R d and R e are attached to each other to form an aromatic ring system, then R V is selected from N(R 5 )2 or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more adjacent substituents R 2 and R IV .

[0160] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula II-1 a:

[0161]

[0162] wherein R 3 is C6-C 5 aryl which is optionally substituted with one or more substituents R 18 ;

[0163] Q 1 is selected from C and CR III .consisting of C and CR

[0164] Q 2 consisting of C and CR II consisting of C and CR

[0165] Q 3 consisting of C and CR I consisting of C and CR

[0166] Q 4 consisting of C and CR 1 consisting of C and CR

[0167] consisting of Q 2 and Q 3 is C;

[0168] if exactly one substituent from the group consisting of Q 2 and Q 3 is C, then exactly one substituent from the group consisting of Q 1 and Q 4 is C (and the other is CR III and CR 1 ).

[0169] This means that the structure of formula II-1a consists of the following three structural formulae II-1aa, formula II-1ab and formula II-1ac:

[0170]

[0171] In a more preferred embodiment of the application, the organic molecules comprise or consist of a structure of formula II-1a, wherein at least one substituent from the group consisting of R 2 , R V and R IV forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R V and R IV .

[0172] In a more preferred embodiment of the application, the organic molecules comprise or consist of a structure of formula II-1a, wherein at least one substituent R V forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more adjacent substituents R 2 and R IV .

[0173] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula II-1, wherein at least one substituent selected from the group consisting of R 2 , R V , and R IV forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic, and / or benzo-fused ring system with one or more substituents R 2 , R V , and R IV , wherein the ring system is selected from the group consisting of

[0174]

[0175] wherein each dotted line is a connection point.

[0176] In a preferred embodiment, the connection points are positioned adjacent to each other. This means that R 2 preferably forms a ring system with R V ; R V preferably forms a ring system with R 2 and / or R IV , and R IV preferably forms a ring system with R V .

[0177] In a more preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula II-1, wherein at least one substituent selected from the group consisting of R 2 , R V , and R IV forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic, and / or benzo-fused ring system with one or more substituents R 2 , R V , and R IV , wherein the ring system is selected from the group consisting of

[0178]

[0179] wherein each dotted line is a connection point.

[0180] In an even more preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula II-1, wherein at least one substituent selected from the group consisting of R 2 , R V , and R IV forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic, and / or benzo-fused ring system with one or more substituents R 2 , R V , and R IVforming a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system, wherein the ring system is selected from the group consisting of

[0181]

[0182] wherein X 1 is S, O or NR 5 .

[0183] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula II-1 a: 2 V IV at least one substituent selected from the group consisting of R 2 V IV form a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system, wherein the ring system is selected from the group consisting of

[0184]

[0185] wherein each dashed line is a point of attachment.

[0186] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula II-1 a: 2 V IV at least one substituent selected from the group consisting of R 2 V IV form a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system, wherein the ring system is selected from the group consisting of

[0187]

[0188] wherein each dashed line is a point of attachment.

[0189] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula II-1 ac:

[0190]

[0191] In another embodiment, the organic molecules comprise or consist of a structure of Formula II-1 ab:

[0192]

[0193] ​​​​​​​​In one embodiment of the invention, the organic molecule comprises or is composed of a structure of formula IIa:

[0194]

[0195] in,

[0196] R b Each time it appears, it is independently selected from the group consisting of: hydrogen; deuterium; N(R) 5 )2; OR 5 ;Si(R) 5 )3;B(OR 5 )2; OSO2R 5 ;CF3;CN;F;Br;I;C1-C 40 Alkyl groups, optionally substituted with one or more substituents R 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 P(=O)(R) 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C1-C 40 Alkoxy, optionally substituted with one or more substituents R 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 P(=O)(R) 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C1-C 40 Thioalkoxy groups, optionally substituted with one or more substituents R 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5)2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 substituted; C2-C 40 alkenyl, optionally substituted with one or more substituents R 5 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , CºC, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 substituted; C2-C 40 alkynyl, optionally substituted with one or more substituents R 5 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , CºC, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 substituted; C6-C 60 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 57 heteroaryl, optionally substituted with one or more substituents R 5 .

[0197] In addition, the above definitions apply.

[0198] In yet another embodiment of the application, R b are at each occurrence independently of each other selected from the group consisting of hydrogen; deuterium; Me; i Pr; t Bu; CN; CF3; Ph, optionally substituted with one or more substituents independently of each other selected from Me, i Pr, tBu, CN, CF3and Ph; pyridyl, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t Bu, CN, CF3and Ph; carbazolyl, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t Bu, CN, CF3and Ph; triazinyl, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t Bu, CN, CF3and Ph; and N(Ph)2.

[0199] In a further embodiment of the application, R b are independently of each other in each occurrence selected from the group consisting of Me; i Pr; t Bu; CN; CF3; Ph, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t Bu, CN, CF3and Ph; pyridyl, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t Bu, CN, CF3and Ph; carbazolyl, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t Bu, CN, CF3and Ph; triazinyl, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr, t Bu, CN, CF3and Ph; and N(Ph)2.

[0200] In a preferred embodiment, the organic light emitting molecule of the application comprises or consists of a structure of formula IIa, and with the proviso that if X is NR 3 and R d and R e are linked to each other to form an aromatic ring system, then R V is selected from N(R 5 )2 or one or more substituents R 2 , R 3 , R 5 and R IVform a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system.

[0201] In preferred embodiments of the application, the organic molecules comprise or consist of a structure of Formula III:

[0202]

[0203] wherein the substituents R a and R 5 independently of one another are optionally substituted with one or more substituents R a and R 5 form a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system; and

[0204] wherein the substituents R 1 , R 2 , R 3 , R 4 , R 5 , R I , R II , R III , R IV and R V independently of one another are optionally substituted with one or more substituents R 1 , R 2 , R 3 , R 4 , R 5 , R I , R II , R III , R IV and R V form a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system.

[0205] In preferred embodiments, the organic light-emitting molecules of the application comprise or consist of a structure of Formula III, with the proviso that if X is NR 3 then R V is selected from N(R 5 )2or forms a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0206] In preferred embodiments of the application, the organic molecules comprise or consist of a structure of Formula III-1:

[0207]

[0208] wherein R 3 is C6-C 6 aryl which is optionally substituted with one or more substituents R 60 .

[0209] In preferred embodiments, the inventive organic light-emitting molecule comprises or consists of a structure of formula III-1, wherein R V is selected from N(R 5 )2 or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0210] In preferred embodiments of the application, the organic molecule comprises or consists of a structure of formula III-2:

[0211]

[0212]

[0213] wherein R 3 is C6-C 5 aryl which is optionally substituted with one or more substituents R 18 .

[0214] In preferred embodiments of the application, the organic molecule comprises or consists of a structure of formula III-2, wherein R 3 is C6-C 6 aryl which is optionally substituted with one or more substituents R 18 ,

[0215] and R V is selected from the group consisting of C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 ; and N(R 5 )2.

[0216] In preferred embodiments, the inventive organic light-emitting molecule comprises or consists of a structure of formula III-2, wherein R V is selected from N(R 5 )2 or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0217] In a preferred embodiment, the organic molecules comprise or consist of a structure of Formula III-2, wherein R V is N(C6-C 18 aryl)2.

[0218] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula III-2a:

[0219]

[0220] wherein,

[0221] is at least one substituent selected from the group consisting of R 1 , R 2 , R I , R II , R III , R IV and R V forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 1 , R 2 , R 3 , R 4 , R 5 , R I , R II , R III , R IV and R V selected from the group consisting of:

[0222]

[0223] wherein each dashed line is a connection point.

[0224] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula III-2a, wherein R 3 is C6-C 5 aryl which is optionally substituted with one or more substituents R 18 and

[0225] wherein is at least one substituent selected from the group consisting of R 1 , R 2 , R I , R II , R III , R IV and R V forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 1 , R 2 , R3 4 5 I II III IV V form a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system, wherein the ring system is selected from the group consisting of

[0226]

[0227] wherein each dotted line is a point of attachment.

[0228] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula III-2b:

[0229]

[0230] In a more preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula III-2b, wherein at least one substituent selected from the group consisting of R 2 V IV and one or more substituents R 2 V IV form a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system, wherein the ring system is selected from the group consisting of

[0231]

[0232] wherein each dotted line is a point of attachment.

[0233] In an even more preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula III-2b, wherein at least one substituent selected from the group consisting of R 2 V IV and one or more substituents R 2 V IV form a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system, wherein the ring system is selected from the group consisting of

[0234]

[0235] wherein each dotted line is a point of attachment.

[0236] ​​​​​​​​​​​​​​​In a particular embodiment of the invention, the organic molecules comprise or consist of a structure of Formula III-2b, wherein at least one substituent selected from the group consisting of R 2 , R V , and R IV forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic, and / or benzo-fused ring system with one or more substituents R 2 , R V , and R IV , wherein the ring system is selected from the following group:

[0237]

[0238] wherein each dotted line is a point of attachment.

[0239] In one embodiment of the invention, the organic molecules / oligomers comprise or consist of a structure of Formula III-2b, wherein at least one R a is different from hydrogen.

[0240] In a preferred embodiment of the invention, the organic molecules comprise or consist of a structure of Formula III-2c:

[0241]

[0242] In a more preferred embodiment of the invention, the organic molecules comprise or consist of a structure of Formula III-2c, wherein at least one substituent selected from the group consisting of R 2 , R V , and R IV forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic, and / or benzo-fused ring system with one or more substituents R 2 , R V , and R IV , wherein the ring system is selected from the following group:

[0243]

[0244] wherein each dotted line is a point of attachment.

[0245] In an even more preferred embodiment of the invention, the organic molecules comprise or consist of a structure of Formula III-2c, wherein at least one substituent selected from the group consisting of R 2 , R V , and R IV forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic, and / or benzo-fused ring system with one or more substituents R 2 , R V , and R IVforming a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system, wherein the ring system is selected from the group consisting of:

[0246]

[0247] wherein each dotted line is a point of attachment.

[0248] In a particularly preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula III-2c, wherein at least one substituent selected from the group consisting of R 2 , R V and R IV forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R V and R IV , wherein the ring system is selected from the group consisting of:

[0249]

[0250] wherein each dotted line is a point of attachment.

[0251] In a particularly preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula III-2c, wherein at least one substituent selected from the group consisting of R 2 , R V and R IV forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R V and R IV , wherein the ring system is selected from the group consisting of:

[0252]

[0253] wherein each dotted line is a point of attachment.

[0254] In one embodiment of the application, the organic molecules / oligomers comprise or consist of a structure of Formula III-2c, wherein at least one R a is different from hydrogen.

[0255] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula III-2d-I, Formula III-2d-II, Formula III-2d-III and Formula III-2d-IV:

[0256]

[0257] In one embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of Formula III-2d-I, Formula III-2d-II, Formula III-2d-III, and Formula III-2d-IV, wherein at least one R a is different from hydrogen.

[0258] In one embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of Formula III-2d-I, Formula III-2d-II, Formula III-2d-III, and Formula III-2d-IV, wherein X 1 is O.

[0259] In a more preferred embodiment of the invention, the organic molecule comprises or consists of a structure of Formula III-2d-III:

[0260]

[0261] In one embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of Formula III-2d-III, wherein at least one R a is different from hydrogen.

[0262] In one embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of Formula III-2d-III, wherein X 1 is O.

[0263] In a more preferred embodiment of the invention, the organic molecule comprises or consists of a structure of Formula III-2d-IIIa:

[0264]

[0265] In one embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of Formula III-2d-IIIa, wherein at least one R a is different from hydrogen.

[0266] In one embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of Formula III-2d-IIIa, wherein X1 is O.

[0267] In a further preferred embodiment of the invention, the organic molecules comprise or consist of a structure of formula III-2d-IIIb:

[0268]

[0269] In one embodiment of the invention, the organic molecules / oligomers comprise or consist of a structure of formula III-2d-IIIb, wherein at least one R a is different from hydrogen.

[0270] In one embodiment of the invention, the organic molecules / oligomers comprise or consist of a structure of formula III-2d-IIIb, wherein X 1 is O.

[0271] In a particular embodiment of the invention, the organic molecules comprise or consist of a structure of formula III-2d-IIIc:

[0272]

[0273] In one embodiment of the invention, the organic molecules / oligomers comprise or consist of a structure of formula III-2d-IIIc, wherein at least one R a is different from hydrogen.

[0274] In one embodiment of the invention, the organic molecules / oligomers comprise or consist of a structure of formula III-2d-IIIc, wherein X 1 is O.

[0275] In another preferred embodiment of the invention, the organic molecules comprise or consist of a structure of formula III-3, formula III-4, or formula III-5:

[0276]

[0277] In one embodiment, the organic molecules comprise or consist of a structure of formula III-3, formula III-4, or formula III-5, wherein R Vselected from the group consisting of OPh; CF3; CN; F; C1-C5 alkyl, wherein one or more hydrogen atoms are optionally substituted independently from each other with deuterium, CN, CF3, or F; C1-C5 alkoxy, wherein one or more hydrogen atoms are optionally substituted independently from each other with deuterium, CN, CF3, or F; C1-C5 thioalkoxy, wherein one or more hydrogen atoms are optionally substituted independently from each other with deuterium, CN, CF3, or F; C2-C5 alkenyl, wherein one or more hydrogen atoms are optionally substituted independently from each other with deuterium, CN, CF3, or F; C2-C5 alkynyl, wherein one or more hydrogen atoms are optionally substituted independently from each other with deuterium, CN, CF3, or F; C6-C 18 aryl, optionally substituted with one or more C1-C5 alkyl substituents; C2-C 17 heteroaryl, optionally substituted with one or more C1-C5 alkyl substituents; N(C6-C 18 aryl)2; N(C2-C 17 heteroaryl)2; and N(C2-C 17 heteroaryl)(C6-C 18 aryl).

[0278] Different exemplary embodiments for formula III are shown in the following:

[0279]

[0280]

[0281] wherein the substituents R a and R 5 are independently from each other optionally forming a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R a and R 5 are independently from each other optionally forming a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R

[0282] and wherein in addition any of the above definitions apply.

[0283] Additional examples of organic molecules:

[0284]

[0285]

[0286]

[0287]

[0288] wherein in addition any of the above definitions apply.

[0289] In one embodiment, R a and R 5 are at each occurrence independently of each other selected from the group consisting of hydrogen (H), methyl (Me), isopropyl (CH(CH3)2) i Pr), tert-butyl ( t Bu), phenyl (Ph), CN, CF3, and diphenylamino (NPh2).

[0290] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula IIIa:

[0291]

[0292] In a preferred embodiment, the inventive organic light emitting molecules comprise or consist of a structure of Formula IIIa, and with the proviso that if X is NR 3 , then R V is selected from N(R 5 )2or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0293] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure selected from the group consisting of Formula IIIa-1 and Formula IIIa-2:

[0294]

[0295] In a preferred embodiment, the inventive organic light emitting molecules comprise or consist of a structure of Formula IIIa-1 or Formula IIIa-2, and with the proviso that if X is NR 3 , then R V is selected from N(R 5 )2or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0296] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula IIIb:

[0297]

[0298] In preferred embodiments, the inventive organic light emitting molecule comprises or consists of a structure of formula IIIb, wherein R V is selected from N(R 5 )2 or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0299] In preferred embodiments of the invention, the organic molecule comprises or consists of a structure selected from the group consisting of formula IIIb-1 and formula IIIb-2:

[0300]

[0301] In preferred embodiments, the inventive organic light emitting molecule comprises or consists of a structure of formula IIIb-1 or formula IIIb-2, wherein R V is selected from N(R 5 )2 or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0302] In preferred embodiments of the invention, the organic molecule comprises or consists of a structure of formula IIIc:

[0303]

[0304] In preferred embodiments, the inventive organic light emitting molecule comprises or consists of a structure of formula IIIc, with the proviso that if X is NR 3 , then R V is selected from N(R 5 )2 or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 and R 5 .

[0305] In preferred embodiments of the invention, the organic molecule comprises or consists of a structure selected from the group consisting of formula IIIc-1 and formula IIIc-2:

[0306]

[0307] In preferred embodiments, the inventive organic light emitting molecule comprises or consists of a structure of Formula IIIc-1 or Formula IIIc-2, and with the proviso that if X is NR 3 then R V is selected from N(R 5 )2or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 and R 5 .

[0308] In preferred embodiments of the invention, the organic molecule comprises or consists of a structure of Formula IIId:

[0309]

[0310] In preferred embodiments, the inventive organic light emitting molecule comprises or consists of a structure of Formula IIId, wherein R V is selected from N(R 5 )2or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 and R 5 .

[0311] In preferred embodiments of the invention, the organic molecule comprises or consists of a structure selected from the group consisting of Formula IIId-1 and Formula IIId-2:

[0312]

[0313] In preferred embodiments, R V is selected from the group consisting of C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 ; and N(R 5 )2.

[0314] In preferred embodiments, the inventive organic light emitting molecule comprises or consists of a structure of Formula IIId-1 or Formula IIId-2, wherein R V is selected from N(R 5 )2or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 .and R 5 form a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system.

[0315] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula IIIe-0:

[0316]

[0317] Q 1 is selected from the group consisting of C and CR III ;

[0318] Q 2 is selected from the group consisting of C and CR II ;

[0319] Q 3 is selected from the group consisting of C and CR I ;

[0320] Q 4 is selected from the group consisting of C and CR 1 ;

[0321] wherein at least one substituent selected from the group consisting of Q 2 and Q 3 is C;

[0322] if exactly one substituent selected from the group consisting of Q 2 and Q 3 is C, then exactly one substituent selected from the group consisting of Q 1 and Q 4 is C and the other is CR III or CR 1 .

[0323] In one embodiment, the inventive organic light-emitting molecule comprises or consists of a structure of Formula IIIe-0, wherein R V is selected from N(R 5 )2 or forms a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0324] In one embodiment, the inventive organic light-emitting molecule comprises or consists of a structure of Formula IIIe-0, wherein R V forms a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R5 and R IV form a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system.

[0325] In one embodiment, the inventive organic light-emitting molecule comprises or consists of a structure of formula IIIe-0, wherein at least one substituent selected from the group consisting of R 1 , R 2 , R III , R IV and R V form a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 1 , R 2 , R 3 , R 4 , R 5 , R I , R II , R III , R IV and R V .

[0326] In one embodiment, the inventive organic light-emitting molecule comprises or consists of a structure of formula IIIe-0, wherein R 3 are independently of each other selected from the group consisting of C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 .

[0327] In one embodiment, the inventive organic light-emitting molecule comprises or consists of a structure of formula IIIe-0, wherein R 3 are independently of each other selected from the group consisting of C6-C 18 aryl, optionally substituted with one or more substituents R 5 .

[0328] In one embodiment, the inventive organic light-emitting molecule comprises or consists of a structure of formula IIIe-0, wherein Q 4 is CR 1 .

[0329] In one embodiment, the inventive organic light-emitting molecule comprises or consists of a structure of formula IIIe-0, wherein R a are independently of each other at each occurrence selected from the group consisting of hydrogen; deuterium; N(R 5)2; OR 5 ;SR 5 ;Si(R) 5 )3;B(OR 5 )2;B(R 5 )2; OSO2R 5 ;CF3;CN;halogen;C1-C 18 Alkyl groups, optionally substituted with one or more substituents R 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 P(=O)(R) 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C1-C 18 Alkoxy, optionally substituted with one or more substituents R 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 P(=O)(R) 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C1-C 18 Thioalkoxy groups, optionally substituted with one or more substituents R 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 P(=O)(R) 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C2-C 18 Alkenyl, optionally substituted with one or more substituents R 5And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 P(=O)(R) 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C2-C 18 The alkynyl group may optionally be substituted with one or more substituents R. 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 P(=O)(R) 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 Heteroaryl, optionally substituted with one or more substituents R 5 .

[0330] In one embodiment, the organic light-emitting molecule of the invention comprises or is composed of a structure of formula IIIe-0, wherein R a Each time it appears, it is independently selected from the group consisting of: hydrogen; deuterium; C1-C. 18 Alkyl groups, optionally substituted with one or more substituents R 5 C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 Heteroaryl, optionally substituted with one or more substituents R 5 .

[0331] In one embodiment, the organic light-emitting molecule of the invention comprises or is composed of a structure of formula IIIe-0, wherein R a Each time it appears, it is independently selected from the group consisting of: hydrogen; deuterium; and C1-C. 18alkyl, optionally substituted with one or more substituents R 5 .

[0332] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of Formula IIIe-0, wherein R 1 , R 2 , R 3 , R 4 , R I , R II , R III , R IV and R V are independently from each other selected from the group consisting of hydrogen; deuterium; N(R 5 )2; OR 5 ; Si(R 5 )3; B(R 5 )2; CF3; CN; halogen; C1-C 18 alkyl, optionally substituted with one or more substituents R 5 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 ; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 ; and

[0333] R 5 is at each occurrence independently from each other selected from the group consisting of hydrogen; deuterium; N(R 6 )2; OR 6 ; Si(R 6 )3; B(R 6 )2; CF3; CN; F; Br; I; C1-C 18 alkyl, optionally substituted with one or more substituents R 6 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 6 C=CR 6 , C≡C, Si(R 6)2, Ge(R 6 )2, Sn(R 6 )2, C=0, C=S, C=Se, C=NR 6 , P(=0)(R 6 ), SO, S02, NR 6 , O, S or CONR 6 substituted; C6-C 18 aryl, optionally substituted with one or more substituents R 6 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 6 ,

[0334] wherein the groups R 1 , R 2 , R 3 , R I , R II , R III , R IV , R 5 and R V are optionally bound to each other to form an aromatic or heteroaromatic ring, optionally substituted with one or more C1-C5 alkyl substituents, deuterium, halogen, CN or CF3.

[0335] This means that the structure of formula IIIe-0 consists of the following three structural formulae IIIe-0a, formula IIIe and formula IIIe-0b:

[0336]

[0337] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of formula IIIe-0b:

[0338]

[0339] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of formula IIIe:

[0340]

[0341] In one embodiment, the organic luminescent molecules of the application comprise or consist of a structure of formula IIIe, wherein R V is selected from N(R 5 )2or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0342] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of Formula IIIe, wherein R V one or more substituents R 2 , R 3 , R 5 and R IV form a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system.

[0343] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of Formula IIIe, wherein at least one substituent selected from the group consisting of R 1 , R 2 , R III , R IV and R V forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 1 , R 2 , R 3 , R 4 , R 5 , R I , R II , R III , R IV and R V .

[0344] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of Formula IIIe, wherein R 3 are at each occurrence independently of each other selected from the group consisting of C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 .

[0345] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of Formula IIIe, wherein R 3 are at each occurrence independently of each other selected from the group consisting of C6-C 18 aryl, optionally substituted with one or more substituents R 5 .

[0346] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of Formula IIIe, wherein R a are at each occurrence independently of each other selected from the group consisting of hydrogen; deuterium; N(R5 )2; OR 5 ;SR 5 ;Si(R) 5 )3;B(OR 5 )2;B(R 5 )2; OSO2R 5 ;CF3;CN;halogen;C1-C 18 Alkyl groups, optionally substituted with one or more substituents R 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 P(=O)(R) 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C1-C 18 Alkoxy, optionally substituted with one or more substituents R 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 P(=O)(R) 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C1-C 18 Thioalkoxy groups, optionally substituted with one or more substituents R 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 P(=O)(R) 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C2-C 18 Alkenyl, optionally substituted with one or more substituents R 5and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , CºC, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; C2-C 18 alkynyl, which is optionally substituted with one or more substituents R 5 and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , CºC, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; C6-C 18 aryl, which is optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, which is optionally substituted with one or more substituents R 5 .

[0347] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of Formula IIIe, wherein R a at each occurrence is independently selected from the group consisting of hydrogen; deuterium; C1-C 18 alkyl, which is optionally substituted with one or more substituents R 5 ; C6-C 18 aryl, which is optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, which is optionally substituted with one or more substituents R 5 .

[0348] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of Formula IIIe, wherein R a at each occurrence is independently selected from the group consisting of hydrogen; deuterium; C1-C 18 alkyl, which is optionally substituted with one or more substituents R5 .

[0349] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of Formula IIIe, wherein R 1 , R 2 , R 3 , R 4 , R I , R II , R III , R IV and R V are independently from each other selected from the group consisting of hydrogen, deuterium, N(R 5 )2, OR 5 , Si(R 5 )3, B(R 5 )2, CF3, CN, halogen, C1-C 18 alkyl, optionally substituted with one or more substituents R 5 , and wherein one or more non-adjacent CH2groups are optionally substituted with R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 ; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 ; and

[0350] R 5 is at each occurrence independently from each other selected from the group consisting of hydrogen, deuterium, N(R 6 )2, OR 6 , Si(R 6 )3, B(R 6 )2, CF3, CN, F, Br, I, C1-C 18 alkyl, optionally substituted with one or more substituents R 6 , and wherein one or more non-adjacent CH2groups are optionally substituted with R 6 C=CR 6 , C≡C, Si(R 6 )2, Ge(R 6)2, Sn(R 6 )2, C=0, C=S, C=Se, C=NR 6 6 )2, SO, S02, NR 6 6 , O, S or CONR 18 ; C6-C 6 aryl, optionally substituted with one or more substituents R 17 ; and C2-C 6 heteroaryl, optionally substituted with one or more substituents R

[0351] wherein the groups R 1 , R 2 , R 3 , R I , R II , R III , R IV , R 5 and R V are optionally bound to each other to form an aromatic or heteroaromatic ring, optionally substituted with one or more C1-C5 alkyl substituents, deuterium, halogen, CN or CF3.

[0352] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula IIIe-2:

[0353]

[0354] In one embodiment, the inventive organic light-emitting molecule comprises or consists of a structure of Formula IIIe-2, wherein R V is selected from N(R 5 )2or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0355] In one embodiment, the inventive organic light-emitting molecule comprises or consists of a structure of Formula IIIe-2, wherein R V forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0356] ​​In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of Formula IIIe-2, wherein at least one substituent selected from the group consisting of R 1 , R 2 , R III , R IV , and R V forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 1 , R 2 , R 3 , R 4 , R 5 , R I , R II , R III , R IV , and R V .

[0357] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of Formula IIIe-2, wherein R 3 is at each occurrence independently of each other selected from the group consisting of C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 .

[0358] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of Formula IIIe-2, wherein R 3 is at each occurrence independently of each other selected from the group consisting of C6-C 18 aryl, optionally substituted with one or more substituents R 5 .

[0359] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of Formula IIIe-2, wherein R a is at each occurrence independently of each other selected from the group consisting of hydrogen; deuterium; N(R 5 )2; OR 5 ; SR 5 ; Si(R 5 )3; B(OR 5 )2; B(R 5 )2; OSO2R 5 ; CF3; CN; halogen; C1-C 18 alkyl, optionally substituted with one or more substituents R 5 .and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C=C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; C1-C 18 alkyl, optionally substituted with one or more substituents R 5 and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C=C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; C1-C 18 thioalkoxy, optionally substituted with one or more substituents R 5 and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C=C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; C2-C 18 alkenyl, optionally substituted with one or more substituents R 5 and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C=C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR5 O, S or CONR 5 substituted; C2-C 18 alkynyl, which is optionally substituted with one or more substituents R 5 and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , CºC, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 O, S or CONR 5 substituted; C6-C 18 aryl, which is optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, which is optionally substituted with one or more substituents R 5 .

[0360] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of formula IIIe-2, wherein R a are at each occurrence independently from each other selected from the group consisting of: hydrogen, deuterium, halogen, nitrogen, oxygen or sulfur; C1-C 18 alkyl, which is optionally substituted with one or more substituents R 5 ; C6-C 18 aryl, which is optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, which is optionally substituted with one or more substituents R 5 .

[0361] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of formula IIIe-2, wherein R a are at each occurrence independently from each other selected from the group consisting of: hydrogen, deuterium, and C1-C 18 alkyl, which is optionally substituted with one or more substituents R 5 .

[0362] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of formula IIIe-2, wherein R 1 , R 2 , R 3 , R 4 , R I , R IIR III R IV and R V are independently from each other selected from the group consisting of hydrogen, deuterium, N(R 5 )2, OR 5 , Si(R 5 )3, B(R 5 )2, CF3, CN, halogen, C1-C 18 alkyl, optionally substituted with one or more substituents R 5 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 ; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 ; and

[0363] R 5 is at each occurrence independently selected from the group consisting of hydrogen, deuterium, N(R 6 )2, OR 6 , Si(R 6 )3, B(R 6 )2, CF3, CN, F, Br, I, C1-C 18 alkyl, optionally substituted with one or more substituents R 6 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 6 C=CR 6 , C≡C, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=O, C=S, C=Se, C=NR 6 , P(=O)(R 6 ), SO, SO2, NR 6 , O, S or CONR 6 ; C6-C 18 aryl, optionally substituted with one or more substituents R 6; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 6 ,

[0364] wherein the groups R 1 , R 2 , R 3 , R I , R II , R III , R IV , R 5 and R V are optionally bound to each other to form an aromatic or heteroaromatic ring, optionally substituted with one or more C1-C5 alkyl substituents, deuterium, halogen, CN or CF3.

[0365] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula IIIe-3:

[0366]

[0367] In a preferred embodiment of the application, the organic molecules comprise or consist of a structure of Formula IIIe-4:

[0368]

[0369] In one embodiment, the inventive organic light-emitting molecules comprise or consist of a structure of Formula IIIe-4, wherein R V is selected from N(R 5 )2 or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0370] In one embodiment, the inventive organic light-emitting molecules comprise or consist of a structure of Formula IIIe-4, wherein R V forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0371] In one embodiment, the inventive organic light-emitting molecules comprise or consist of a structure of Formula IIIe-4, wherein R 1 , R 2 , RIII R IV and R V At least one substituent in the group consists of one or more substituents R 1 R 2 R 3 R 4 R 5 R I R II R III R IV and R V Forming monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo[a] fused ring systems.

[0372] In one embodiment, the invented organic light-emitting molecule comprises or is composed of a structure of formula IIIe-4, wherein R 3 They are selected independently from the following groups: C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 Heteroaryl, optionally substituted with one or more substituents R 5 .

[0373] In one embodiment, the invented organic light-emitting molecule comprises or is composed of a structure of formula IIIe-4, wherein R 3 They are selected independently from the following groups: C6-C 18 aryl, optionally substituted with one or more substituents R 5 .

[0374] In one embodiment, the invented organic light-emitting molecule comprises or is composed of a structure of formula IIIe-4, wherein R a Each time it appears, it is independently selected from the group consisting of: hydrogen; deuterium; N(R) 5 )2; OR 5 ;SR 5 ;Si(R) 5 )3;B(OR 5 )2;B(R 5 )2; OSO2R 5 ;CF3;CN;halogen;C1-C 18 Alkyl groups, optionally substituted with one or more substituents R 5 And wherein one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5)2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 )2, P(=0)(R 5 )2, SO, S02, NR 5 )2, 0, S or CONR 5 substituted; Ci-C 18 alkyl, which is optionally substituted with one or more substituents R 5 and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 )2, P(=0)(R 5 )2, SO, S02, NR 5 )2, 0, S or CONR 5 substituted; Ci-C 18 thioalkoxy, which is optionally substituted with one or more substituents R 5 and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 )2, P(=0)(R 5 )2, SO, S02, NR 5 )2, 0, S or CONR 5 substituted; C2-C 18 alkenyl, which is optionally substituted with one or more substituents R 5 and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 )2, P(=0)(R 5 )2, SO, S02, NR 5 )2, 0, S or CONR 5 substituted; C2-C 18 alkynyl, which is optionally substituted with one or more substituents R 5and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , CºC, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 .

[0375] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of formula IIIe-4, wherein R a is at each occurrence independently from each other selected from the group consisting of: hydrogen, deuterium, halogen, nitrogen, oxygen, phosphorus, sulfur, silicon, selenium, tellurium, boron, carbon, boron, nitrogen, oxygen, phosphorus, sulfur, silicon, selenium, tellurium; C1-C 18 alkyl, optionally substituted with one or more substituents R 5 ; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 .

[0376] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of formula IIIe-4, wherein R a is at each occurrence independently from each other selected from the group consisting of: hydrogen, deuterium, and C1-C 18 alkyl, optionally substituted with one or more substituents R 5 .

[0377] In one embodiment, the inventive organic light emitting molecule comprises or consists of a structure of formula IIIe-4, wherein R 1 , R 2 , R 3 , R 4 , R I , R II , R III , R IV and R V are independently from each other selected from the group consisting of: hydrogen, deuterium, N(R 5)2; OR 5 ; Si(R 5 )3; B(R 5 )2; CF3; CN; halogen; C1-C 18 alkyl, which is optionally substituted with one or more substituents R 5 , and where one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; C6-C 18 aryl, which is optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, which is optionally substituted with one or more substituents R 5 ; and

[0378] R 5 is at each occurrence and independently from occurrence to occurrence selected from the group consisting of: hydrogen; deuterium; N(R 6 )2; OR 6 ; Si(R 6 )3; B(R 6 )2; CF3; CN; F; Br; I; C1-C 18 alkyl, which is optionally substituted with one or more substituents R 6 , and where one or more non-adjacent CH2groups are optionally substituted by R 6 C=CR 6 , C≡C, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=0, C=S, C=Se, C=NR 6 , P(=0)(R 6 ), SO, S02, NR 6 , O, S or CONR 6 ; C6-C 18 aryl, which is optionally substituted with one or more substituents R 6 ; and C2-C 17 heteroaryl, which is optionally substituted with one or more substituents R 6 ,

[0379] wherein the groups R 1 , R 2 , R 3 , R I , R II , R III , R IV , R 5 and R V are optionally bound to each other to form an aromatic or heteroaromatic ring which is optionally substituted with one or more C1-C5 alkyl substituents, deuterium, halogen, CN or CF3.

[0380] In preferred embodiments, at least one substituent selected from the group consisting of R 1 , R 2 , R 3 , R 4 , R I , R II , R III , R IV and R V is different from hydrogen.

[0381] The present application also provides an oligomer for use as an emitter in an optoelectronic device. The oligomer comprises or consists of a plurality (i.e. 2, 3, 4, 5 or 6) of units represented by formula IV:

[0382]

[0383] The oligomer is a dimer to hexamer (m = 2 to 6), in particular a dimer to trimer (m = 2 or 3), or preferably a dimer (m = 2). The oligomer:

[0384] - can be in the form of a plurality of units as represented by formula IV; or

[0385] - can be in the form wherein a plurality of units as represented by formula IV are connected via a linker selected from the group consisting of a single bond, an alkylene group having 1 to 3 carbon atoms, a phenylene group, a naphthylene group, an anthrylene group, a pyrenylene group, a pyridylene group, a pyrimidylene group or a triazinylene group; or

[0386] - can be in the form wherein the plurality of units are connected such that ring a and / or ring b comprised in the unit according to formula I-AB is shared by at least one other adjacent unit of the oligomer; or

[0387]

[0388] - can be in the form wherein the units of the oligomer are connected such that ring a and / or ring b of a unit is fused to ring a and / or ring b of an adjacent unit of the oligomer;

[0389] - can be in a form in which units of the oligomer are connected such that ring a and / or ring b and / or ring c of a unit comprised according to formula I-ABC is shared with at least one other adjacent unit of the oligomer; or

[0390]

[0391] - can be in a form in which units of the oligomer are connected such that ring a and / or ring b and / or ring c of a unit is fused with ring a and / or ring b and / or ring c of an adjacent unit of the oligomer,

[0392] wherein, if ring b and ring c of one unit of the oligomer are shared with ring b and ring c of an adjacent oligomer, the direct bond between ring b and ring c can also be shared, as shown in the following exemplary structures:

[0393]

[0394] and wherein any substituent R a , R d , R e , R IV , R V , R 2 , R 1 , R I , R II , R III , R 3 or R 4 of a unit shown in formula IV a , R d , R e , R IV , R V , R 2 , R 1 , R I , R II , R III , R 3 or R 4 can be bound to any substituent R a , R d , R e , R IV , R V , R 2 , R 1 , R I , R II , R III , R 3 or R 4 of an adjacent unit to form a direct bond or an aromatic or heteroaromatic ring optionally substituted with one or more C1-C5 alkyl substituents, Ph, deuterium, halogen, CN or CF3,

[0395] and wherein two adjacent rings can also share a bond;

[0396] Different examples are shown below:

[0397]

[0398] In some embodiments of the oligomer, a portion of the units shown in Formula VI (ring a and / or ring b and / or ring c) are combined so as to be shared by adjacent units, as shown in the following exemplary structures:

[0399]

[0400]

[0401]

[0402] Additional examples of oligomers according to the application in the form of dimers (m = 2):

[0403]

[0404]

[0405] In one embodiment of the application, the oligomer comprises or consists of a structure selected from the group consisting of:

[0406]

[0407]

[0408]

[0409]

[0410]

[0411]

[0412]

[0413]

[0414]

[0415]

[0416] In a particular embodiment of the application, the oligomer is a dimer or a trimer (m = 3) (preferably a dimer).

[0417] In preferred embodiments, R 1 , R 2 , R 3 , R 4 , R I , R II , R III , R IV and RV They are selected independently from the group consisting of: hydrogen; deuterium; N(R) 5 )2; OR 5 ;Si(R) 5 )3;B(R 5 )2; CF3; CN; Halogen; C1-C 18 Alkyl groups, optionally substituted with one or more substituents R 5 And wherein, one or more non-adjacent CH2 groups are optionally R 5 C = CR 5 C≡C, Si(R) 5 )2、Ge(R 5 )2、Sn(R 5 )2. C=O, C=S, C=Se, C=NR 5 、P(=O)(R 5 SO, SO2, NR 5 O, S or CONR 5 Replacement; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 Heteroaryl, optionally substituted with one or more substituents R 5 ;and

[0418] R 5 Each time it appears, it is independently selected from the group consisting of: hydrogen; deuterium; N(R) 6 )2; OR 6 ;Si(R) 6 )3;B(R 6 )2;CF3;CN;F;Br;I;C1-C 18 Alkyl groups, optionally substituted with one or more substituents R 6 And wherein, one or more non-adjacent CH2 groups are optionally R 6 C = CR 6 C≡C, Si(R) 6 )2、Ge(R 6 )2、Sn(R 6 )2. C=O, C=S, C=Se, C=NR 6 、P(=O)(R 6 SO, SO2, NR 6 O, S or CONR 6 Replacement; C6-C 18 aryl, optionally substituted with one or more substituents R 6 ; and C2-C 17heteroaryl, optionally substituted with one or more substituents R 6 ,

[0419] wherein the groups R 1 , R 2 , R 3 , R I , R II , R III , R IV , R 5 and R V are optionally bound to each other to form an aromatic or heteroaromatic ring, optionally substituted with one or more C1-C5alkyl substituents, deuterium, halogen, CN or CF3;

[0420] In particular embodiments of the oligomer, R 1 , R 2 , R 3 , R 4 , R I , R II , R III , R IV and R V are independently from each other selected from the group consisting of hydrogen; deuterium; N(R 5 )2; OR 5 ; Si(R 5 )3; B(R 5 )2; CF3; CN; halogen; C1-C 18 alkyl, optionally substituted with one or more substituents R 5 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 ; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 ; and

[0421] R 5 is at each occurrence independently from each other selected from the group consisting of hydrogen; deuterium; N(R 6 )2; OR 6; Si(R 6 )3; B(R 6 )2; CF3; CN; F; Br; I; C1-C 18 alkyl, which is optionally substituted with one or more substituents R 6 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 6 C=CR 6 , C≡C, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=0, C=S, C=Se, C=NR 6 , P(=0)(R 6 ), SO, S02, NR 6 , O, S, or CONR 6 ; C6-C 18 aryl, which is optionally substituted with one or more substituents R 6 ; and C2-C 17 heteroaryl, which is optionally substituted with one or more substituents R 6 ,

[0422] wherein groups R 1 , R 2 , R I , R II , R III , R IV , R 5 , and R V that are located next to each other are optionally combined with each other to form an aromatic or heteroaromatic ring, which is optionally substituted with one or more C1-C5alkyl substituents, deuterium, halogen, CN, or CF3.

[0423] In particular embodiments of the oligomer, R 1 , R 2 , R 3 , R 4 , R I , R II , R III , R IV , R V , and R a are independently from each other selected from the group consisting of hydrogen; deuterium; N(R 5 )2; OR 5 ; SR 5 ; Si(R 5 )3; B(OR 5 )2; B(R 5 )2; OSO2R 5 ; CF3; CN; halogen; C1-C 18 alkyl.alkyl, optionally substituted with one or more substituents R 5 and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; C1-C 18 alkoxy, optionally substituted with one or more substituents R 5 and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; C1-C 18 thioalkoxy, optionally substituted with one or more substituents R 5 and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5 , P(=0)(R 5 ), SO, S02, NR 5 , O, S or CONR 5 ; C2-C 18 alkenyl, optionally substituted with one or more substituents R 5 and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=0, C=S, C=Se, C=NR 5, P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 substituted; C2-C 18 alkynyl, which is optionally substituted with one or more substituents R 5 , and where one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 substituted; C6-C 18 aryl, which is optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, which is optionally substituted with one or more substituents R 5 ;

[0424] R 5 is at each occurrence and independently from occurrence to occurrence selected from the group consisting of hydrogen, deuterium, N(R 6 )2, OR 6 , Si(R 6 )3, B(OR 6 )2, B(R 6 )2, OSO2R 6 , CF3, CN, F, Br, I, Ci-C 18 alkyl, which is optionally substituted with one or more substituents R 6 , and where one or more non-adjacent CH2groups are optionally substituted by R 6 C=CR 6 , C≡C, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=O, C=S, C=Se, C=NR 6 , P(=O)(R 6 ), SO, SO2, NR 6 , O, S or CONR 6 substituted; Ci-C 18 alkoxy, which is optionally substituted with one or more substituents R 6 , and where one or more non-adjacent CH2groups are optionally substituted by R 6 C=CR6 , CºC, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=0, C=S, C=Se, C=NR 6 , P(=0)(R 6 ), SO, S02, NR 6 , O, S or CONR 6 ; C1-C 18 haloalkyl, optionally substituted with one or more substituents R 6 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 6 C=CR 6 , CºC, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=0, C=S, C=Se, C=NR 6 , P(=0)(R 6 ), SO, S02, NR 6 , O, S or CONR 6 ; C2-C 18 alkenyl, optionally substituted with one or more substituents R 6 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 6 C=CR 6 , CºC, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=0, C=S, C=Se, C=NR 6 , P(=0)(R 6 ), SO, S02, NR 6 , O, S or CONR 6 ; C2-C 18 alkynyl, optionally substituted with one or more substituents R 6 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 6 C=CR 6 , CºC, Si(R 6 )2, Ge(R 6 )2, Sn(R 6 )2, C=0, C=S, C=Se, C=NR 6 , P(=0)(R 6 ), SO, S02, NR 6 , O, S or CONR 6 ; C6-C18 aryl, optionally substituted with one or more substituents R 6 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 6 ;

[0425] wherein the substituents R a , R d , R e and R 5 independently of one another optionally form a mono- or polycyclic, aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R a , R d , R e and R 5 ;

[0426] wherein the substituents R 1 , R 2 , R 3 , R 4 , R 5 , R I , R II , R III , R IV and R V independently of one another optionally form a mono- or polycyclic, aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 1 , R 2 , R 3 , R 4 , R 5 , R I , R II , R III , R IV and R V .

[0427] In one embodiment of the application, the organic molecules consist of dimers or trimers, wherein R 1 , R 2 , R a , R d , R e , R I , R II , R III , R IV and R V are at each occurrence independently of one another selected from the group consisting of hydrogen; Me; i Pr; t Bu; CN; CF3; Ph, optionally substituted with one or more substituents independently of one another selected from the group consisting of Me, i Pr,t The group consisting of Bu, CN, CF3, and Ph; pyridyl, optionally substituted with one or more substituents, said substituents being independently selected from the group consisting of Me, i Pr, t The group consisting of Bu, CN, CF3, and Ph; pyrimidinyl, optionally substituted with one or more substituents, said substituents being independently selected from the group consisting of Me, i Pr, t The group consisting of Bu, CN, CF3, and Ph; carbazoyl group, optionally substituted with one or more substituents, said substituents being independently selected from the group consisting of Me, i Pr, t The group consisting of Bu, CN, CF3, and Ph; triazine group, optionally substituted with one or more substituents, said substituents being independently selected from the group consisting of Me, i Pr, t The group consisting of Bu, CN, CF3 and Ph; and N(Ph)2.

[0428] In one embodiment of the invention, the organic molecule / oligomer includes or is composed of a structure of formula IV, wherein at least one R a Unlike hydrogen.

[0429] In a preferred embodiment, the organic light-emitting molecule of the invention comprises or is composed of the structure of formula IV, provided that X is NR. 3 And R d and R e If they connect to form an aromatic ring system, then R V Selected from N(R) 5 )2 or with one or more substituents R 2 R 3 R 5 and R IV Forming monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo[a] fused ring systems.

[0430] In a preferred embodiment of the invention, the organic molecule / oligomer includes or is composed of a structure of formula IV, wherein X, each time it appears, is independently selected from those consisting of direct bonds, NR... 3 CR 3 R 4 A group consisting of S and O.

[0431] In a more preferred embodiment of the invention, the organic molecule / oligomer includes or is composed of a structure of formula IV, wherein X, each time it appears, is independently selected from those consisting of direct bonds, NR... 3 A group consisting of S and O.

[0432] In particular embodiments of the application, the organic molecule / oligomer comprises or consists of a structure of Formula IV, wherein X is, at each occurrence, independently from each other, selected from the group consisting of a direct bond and NR 3 .

[0433] In particular embodiments of the application, the organic molecule / oligomer comprises or consists of a structure of Formula IV, wherein X is NR 3 .

[0434] In preferred embodiments of the application, the organic molecule / oligomer comprises or consists of a structure of Formula IV, wherein R 3 is, at each occurrence, independently from each other, selected from the group consisting of C1-C 40 alkyl, optionally substituted with one or more substituents R 5 ; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 .

[0435] In preferred embodiments of the application, the organic molecule / oligomer comprises or consists of a structure of Formula IV, wherein R V is, at each occurrence, independently from each other, selected from the group consisting of N(R 5 )2; OR 5 ; C1-C 18 alkyl, optionally substituted with one or more substituents R 5 , and wherein one or more non-adjacent CH2 groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR 5 , O, S or CONR 5 ; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl,

[0436] wherein R V is, at each occurrence, independently from each other, optionally substituted with one or more substituents R 2 and R IVmonocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring systems, optionally substituted with one or more C1-C5 alkyl substituents, deuterium, halogen, CN or CF3.

[0437] In a preferred embodiment of the application, the organic molecules / oligomers comprise or consist of the structure of formula IVa-0 and formula IVb-0 (dimer):

[0438]

[0439]

[0440] In a preferred embodiment of the application, the organic molecules / oligomers comprise or consist of the structure of formula IVa and formula IVb-0:

[0441]

[0442] In one embodiment of the application, the organic molecules / oligomers comprise or consist of the structure of formula IVa and formula IVb-0, wherein at least one R a is different from hydrogen.

[0443] In a preferred embodiment, the organic light emitting molecules of the application comprise or consist of the structure of formula IVa and formula IVb-0, with the proviso that if X is NR 3 and R d and R e are connected to each other to form an aromatic ring system, then R V is selected from N(R 5 )2 or forms a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0444] In a preferred embodiment of the application, the organic molecules / oligomers comprise or consist of the structure of formula IVa and formula IVb-0, wherein X is at each occurrence independently from each other selected from the group consisting of a direct bond, NR 3 , CR 3 R 4 , S and O.

[0445] In a preferred embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVa and IVb-0, wherein X is, at each occurrence independently from each other, selected from the group consisting of a direct bond, NR 3 , S and O.

[0446] In a preferred embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVa and IVb-0, wherein X is, at each occurrence independently from each other, selected from the group consisting of a direct bond, NR 3 .

[0447] In a preferred embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVa and IVb-0, wherein X is NR 3 .

[0448] In a preferred embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVa and IVb-0, wherein R 3 is, at each occurrence independently from each other, selected from the group consisting of C1-C 40 alkyl, optionally substituted with one or more substituents R 5 ; C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; and C2-C 17 heteroaryl, optionally substituted with one or more substituents R 5 .

[0449] In a preferred embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVa and IVb-0, wherein R V is, at each occurrence independently from each other, selected from the group consisting of N(R 5 )2; OR 5 ; C1-C 18 alkyl, optionally substituted with one or more substituents R 5 , and wherein one or more non-adjacent CH2groups are optionally substituted by R 5 C=CR 5 , C≡C, Si(R 5 )2, Ge(R 5 )2, Sn(R 5 )2, C=O, C=S, C=Se, C=NR 5 , P(=O)(R 5 ), SO, SO2, NR5 O, S or CONR 5 substituted; C6-C 18 aryl, which is optionally substituted by one or more substituents R 5 ; and C2-C 17 heteroaryl,

[0450] wherein R V independently of one another, are optionally substituted by one or more substituents R 2 and R IV form a monocyclic or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system, which is optionally substituted by one or more C1-C5 alkyl substituents, deuterium, halogen, CN or CF3.

[0451] In one embodiment of the invention, the organic molecules / oligomers comprise a structure according to Formula IVa-0 (dimer) or consist of a structure according to Formula IVa-0 (dimer):

[0452]

[0453] In a preferred embodiment of the invention, the organic molecules / oligomers comprise a structure according to Formula IVa or consist of a structure according to Formula IVa:

[0454]

[0455] In one embodiment of the invention, the organic molecules / oligomers comprise a structure according to Formula IVa-2 or consist of a structure according to Formula IVa-2:

[0456]

[0457] In one embodiment of the invention, the organic molecules / oligomers comprise a structure according to Formula IVa-3 or consist of a structure according to Formula IVa-3:

[0458]

[0459] In one embodiment of the invention, the organic molecules / oligomers comprise a structure according to Formula IVa-4 or consist of a structure according to Formula IVa-4:

[0460]

[0461] In a preferred embodiment of the invention, the organic molecules / oligomers comprise a structure according to Formula IVb-0 or consist of a structure according to Formula IVb-0:

[0462]

[0463] In a particular embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0, wherein X is NR a is different from hydrogen.

[0464] In a preferred embodiment, the inventive organic light emitting molecule comprises or consists of a structure of formula IVb-0, and with the proviso that if X is NR 3 and R d and R e are connected to each other to form an aromatic ring system, then R V is selected from N(R 5 )2 or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0465] In a preferred embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0, wherein X is at each occurrence independently from each other selected from the group consisting of a direct bond, NR 3 , CR 3 R 4 , S and O.

[0466] In a more preferred embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0, wherein X is at each occurrence independently from each other selected from the group consisting of a direct bond, NR 3 , S and O.

[0467] In a particular embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0, wherein X is at each occurrence independently from each other selected from the group consisting of a direct bond and NR 3 .

[0468] In a particular embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0, wherein X is NR 3 .

[0469] In a more preferred embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0a:

[0470]

[0471] In a preferred embodiment of the application, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0a, wherein X is, at each occurrence independently from each other, selected from the group consisting of a direct bond, NR a is different from hydrogen.

[0472] In a preferred embodiment of the application, the organic luminescent molecule comprises or consists of a structure of formula IVb-0a, and with the proviso that if X is NR 3 and R d and R e are connected to each other to form an aromatic ring system, then R V is selected from N(R 5 )2 or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 , and R IV .

[0473] In a preferred embodiment of the application, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0a, wherein X is, at each occurrence independently from each other, selected from the group consisting of a direct bond, NR 3 , CR 3 R 4 , S and O.

[0474] In a more preferred embodiment of the application, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0a, wherein X is, at each occurrence independently from each other, selected from the group consisting of a direct bond, NR 3 , S and O.

[0475] In a particular embodiment of the application, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0a, wherein X is, at each occurrence independently from each other, selected from the group consisting of a direct bond and NR 3 .

[0476] In a particular embodiment of the application, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0a, wherein X is NR 3 .

[0477] In a preferred embodiment of the application, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0b:

[0478]

[0479] In one embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0b, wherein at least one R a is different from hydrogen.

[0480] In a preferred embodiment, the organic light emitting molecule of the invention comprises or consists of a structure of formula IVb-0b, and with the proviso that if X is NR 3 then R V is selected from N(R 5 )2or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0481] In a preferred embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0b, wherein X is at each occurrence independently from each other selected from the group consisting of a direct bond, NR 3 , CR 3 R 4 , S and O.

[0482] In a more preferred embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0b, wherein X is at each occurrence independently from each other selected from the group consisting of a direct bond, NR 3 , S and O.

[0483] In a particular embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0b, wherein X is at each occurrence independently from each other selected from the group consisting of a direct bond and NR 3 .

[0484] In a particular embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0b, wherein X is NR 3 .

[0485] In a more preferred embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0c:

[0486]

[0487] In one embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0c, wherein at least one R a is different from hydrogen.

[0488] In preferred embodiments, the inventive organic light emitting molecule comprises or consists of a structure of formula IVb-0c, and with the proviso that if X is NR 3 then R V is selected from N(R 5 )2 or forms a mono- or polycyclic aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0489] In preferred embodiments of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0c, wherein X is at each occurrence independently from each other selected from the group consisting of a direct bond, NR 3 , CR 3 R 4 , S and O.

[0490] In more preferred embodiments of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0c, wherein X is at each occurrence independently from each other selected from the group consisting of a direct bond, NR 3 , S and O.

[0491] In particular embodiments of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0c, wherein X is at each occurrence independently from each other selected from the group consisting of a direct bond and NR 3 .

[0492] In particular embodiments of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-0c, wherein X is NR 3 .

[0493] In preferred embodiments of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb:

[0494]

[0495] In preferred embodiments of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-2:

[0496]

[0497] In preferred embodiments of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-3:

[0498]

[0499] In one embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-3, wherein at least one R a is different from hydrogen.

[0500] In a preferred embodiment, the organic luminescent molecule of the present invention comprises or consists of a structure of formula IVb-3, wherein R V is selected from N(R 5 )2 or forms a mono- or polycyclic, aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0501] In a preferred embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-4:

[0502]

[0503] In one embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVb-4, wherein at least one R a is different from hydrogen.

[0504] In a preferred embodiment, the organic luminescent molecule of the present invention comprises or consists of a structure of formula IVb-3, wherein R V is selected from N(R 5 )2 or forms a mono- or polycyclic, aliphatic, aromatic, heteroaromatic and / or benzo-fused ring system with one or more substituents R 2 , R 3 , R 5 and R IV .

[0505] In one embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVc:

[0506]

[0507] In one embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of formula IVc-2:

[0508]

[0509] In one embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of Formula IVd:

[0510]

[0511] In a preferred embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of Formula IVd-2:

[0512]

[0513] In one embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of Formula IVe:

[0514]

[0515] In a preferred embodiment of the invention, the organic molecule / oligomer comprises or consists of a structure of Formula IVe-2:

[0516] DETAILED DESCRIPTION

[0517] As used throughout this application, the terms "aryl" and "aromatic" can be understood in the broadest sense as any monocyclic, bicyclic or polycyclic aromatic moiety. Thus, aryl groups contain from 6 to 60 aromatic ring atoms, and heteroaryl groups contain from 5 to 60 aromatic ring atoms at least one of which is a heteroatom. Nonetheless, throughout the application, the number of aromatic ring atoms can be given as a subscript number in the definition of certain substituents. Specifically, heteroaromatic rings include from one to three heteroatoms. Likewise, the terms "heteroaryl" and "heteroaromatic" can be understood in the broadest sense as any monocyclic, bicyclic or polycyclic heteroaromatic moiety including at least one heteroatom. The heteroatoms can be the same or different at each occurrence and can individually be selected from the group consisting of N, O and S. Thus, the term "arylene" refers to a divalent substituent having two points of attachment to other molecular structures and thus serves as a linking group structure. In the event that a group in an exemplary embodiment is defined differently than the definition given herein (e.g., the number of aromatic ring atoms or the number of heteroatoms differs from the given definition), the definition in the exemplary embodiment will apply. According to the invention, a condensed (cyclic) aromatic polycycle or heteroaromatic polycycle consists of two or more single aromatic rings or heteroaromatic rings that form a polycycle via a condensation reaction.

[0518] Specifically, as used throughout, the term "aryl or heteroaryl" includes groups that can be attached via any position of the aromatic or heteroaromatic group, which group is derived from benzene, naphthalene, anthracene, phenanthrene, pyrene, dihydropyrene, perylene, fluoranthene, benzanthracene, benzophenanthrene, naphthacene, pentacene, benzopyrene, furan, benzofuran, isobenzofuran, dibenzofuran, thiophene, benzothiophene, isobenzothiophene, dibenzothiophene, pyrrole, indole, isoindole, carbazole, pyridine, quinoline, isoquinoline, acridine, phenanthridine, benzo-5,6-quinoline, benzo-6,7-quinoline, benzo-7,8-quinoline, phenothiazine, phenoxazine, pyrazole, indazole, imidazole, benzimidazole, naphthimidazole, phenanthroimidazole, pyridoimidazole, pyrazinoimidazole, quinoxalinoimidazole, oxazole, benzoxazole, naphthoxazole, anthroxazole, phenanthroxazole, isoxazole, 1,2-thiazole, 1,3-thiazole, benzothiazole, pyridazine, benzopyridazine, pyrimidine, benzopyrimidine, 1,3,5-triazine, quinoxaline, pyrazine, phenazine, naphthylidine, carbolin, benzocarbolin, phenanthroline, 1,2,3-triazole, 1,2,4-triazole, benzotriazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,2,3,4-tetrazine, purine, pteridine, indolizine, and benzothiadiazole, or combinations thereof.

[0519] As used throughout, the term "cycloalkyl" can be understood in the broadest sense as any monocyclic, bicyclic or polycyclic ring moiety.

[0520] As used throughout, the term "biphenyl" as a substituent can be understood in the broadest sense as an ortho-biphenyl, meta-biphenyl or para-biphenyl, wherein ortho, meta and para are defined with respect to the binding site to another chemical moiety.

[0521] As used throughout, the term "alkyl" can be understood in the broadest sense as any straight chain, branched or cyclic alkyl substituent. Specifically, the term alkyl includes the substituents methyl (Me), ethyl (Et), n-propyl (n-Pr), isopropyl (i-Pr), cyclopropyl, n-butyl (n-Bu), isobutyl (i-Bu), sec-butyl (s-Bu), t-butyl (t-Bu), n-pentyl (n-Pen), isopentyl (i-Pen), neopentyl (neo-Pen), and the like. n Pr), isopropyl ( i Pr), isopropyl ( n Bu), isobutyl ( i Bu), isobutyl ( s Bu), isobutyl ( tBu), cyclobutyl, 2-methylbutyl, n-pentyl, sec-pentyl, t-pentyl, 2-pentyl, neopentyl, cyclopentyl, n-hexyl, sec-hexyl, t-hexyl, 2-hexyl, 3-hexyl, neohexyl, cyclohexyl, 1 -methylcyclopentyl, 2-methylpentyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, cycloheptyl, 1 -methylcyclohexyl, n-octyl, 2-ethylhexyl, cyclooctyl, 1 -bicyclo[2,2,2]octyl, 2-bicyclo[2,2,2]octyl, 2-(2,6-dimethyl)octyl, 3-(3,7-dimethyl)octyl, adamantyl, 2,2,2-trifluoroethyl, 1,1 -dimethyl-n-hex-1 -yl, 1,1 -dimethyl-n-hept-1 -yl, 1,1 -dimethyl-n-oct-1 -yl, 1,1 -dimethyl-n-dec-1 -yl, 1,1 -dimethyl-n-dodec-1 -yl, 1,1 -dimethyl-n-tetradec-1 -yl, 1,1 -dimethyl-n-hexadec-1 -yl, 1,1 -dimethyl-n-octadec-1 -yl, 1,1 -diethyl-n-hex-1 -yl, 1,1 -diethyl-n-hept-1 -yl, 1,1 -diethyl-n-oct-1 -yl, 1,1 -diethyl-n-dec-1 -yl, 1,1 -diethyl-n-dodec-1 -yl, 1,1 -diethyl-n-tetradec-1 -yl, 1,1 -diethyl-n-hexadec-1 -yl, 1,1 -diethyl-n-octadec-1 -yl, 1 -(n-propyl)-cyclohex-1 -yl, 1 -(n-butyl)-cyclohex-1 -yl, 1 -(n-hexyl)-cyclohex-1 -yl, 1 -(n-octyl)-cyclohex-1 -yl and 1 -(n-decyl)-cyclohex-1 -yl.

[0522] As used throughout, the term "alkenyl" includes straight-chain, branched-chain, and cyclic alkenyl substituents. The term "alkenyl" includes, for example, ethenyl, propenyl, butenyl, pentenyl, cyclopentenyl, hexenyl, cyclohexenyl, heptenyl, cycloheptenyl, octenyl, cyclooctenyl, or cyclooctadienyl.

[0523] As used throughout, the term "alkynyl" includes straight-chain, branched-chain, and cyclic alkynyl substituents. The term "alkynyl" includes, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, or octynyl.

[0524] As used throughout, the term "alkoxy" includes straight-chain, branched-chain, and cyclic alkoxy substituents. The term "alkoxy" includes, for example, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy, and 2-methylbutoxy.

[0525] As used throughout, the term "thioalkoxy" includes straight-chain, branched-chain, and cyclic thioalkoxy substituents in which the O of an alkoxyl group is replaced by S.

[0526] As used throughout, the terms "halogen" and "halo" can be understood in the broadest sense to preferably mean fluorine, chlorine, bromine, or iodine.

[0527] Whenever hydrogen (H) is mentioned herein, hydrogen (H) can also be replaced by deuterium at each occurrence.

[0528] It will be understood that when a molecular fragment is described as a substituent or otherwise attached to another moiety, its name can be written as if it were a fragment (e.g., naphthyl, dibenzofuranyl) or as if it were an entire molecule (e.g., naphthalene, dibenzofuran). As used herein, these different ways of specifying substituents or attached fragments are considered equivalent.

[0529] In one embodiment, the organic molecule according to the invention has an excited state lifetime of no more than 5 ps, no more than 2.5 ps, in particular no more than 2.0 ps, more preferably no more than 1.0 ps, or no more than 0.7 ps in a film of poly(methyl methacrylate) (PMMA) having 1 to 5 wt.-%, in particular having 2 wt.-%, of the organic molecule at room temperature.

[0530] In a further embodiment of the invention, the organic molecule according to the invention has an emission peak in the visible or the nearest ultraviolet range, i.e., in the range of wavelengths from 380 nm to 800 nm, and a full width at half maximum of less than 0.25 eV, preferably less than 0.22 eV, more preferably less than 0.18 eV, even more preferably less than 0.15 eV, or even less than 0.12 eV in a film of poly(methyl methacrylate) (PMMA) having 1 to 5 wt.-%, in particular having 2 wt.-%, of the organic molecule at room temperature.

[0531] The orbital and excited state energies can also be determined by way of experimental methods. The highest occupied molecular orbital energy (E HOMO ) is determined via cyclic voltammetry with a precision of 0.1 eV by methods known to the person skilled in the art. The lowest unoccupied molecular orbital energy (E LUMO ) is calculated as E HOMO + E gap , wherein E gap is determined as follows: for host compounds, unless stated otherwise, the onset of the emission spectrum of a film having 10 wt.-% of the host in poly(methyl methacrylate) (PMMA) is used as E gap . For emitter molecules, E gap is determined as the energy at which the excitation and emission spectra of a film having 1 to 5 wt.-%, in particular having 2 wt.-%, of the emitter in PMMA cross. For organic molecules according to the invention, E gapThe energy at which the excitation spectrum and the emission spectrum of a film determined to have 1 to 5 wt.-%, in particular 2 wt.-%, of the organic molecule in PMMA cross.

[0532] The energy of the first excited triplet state T1 is determined by the onset of the emission spectrum at low temperature, typically at 77 K. For host compounds in which the first excited singlet state and the lowest triplet state differ in energy by > 0.4 eV, phosphorescence is usually visible in the steady state spectrum in 2-Me-THF. Thus, the triplet energy can be determined as the onset of the phosphorescence spectrum. For TADF emitter molecules, the energy of the first excited triplet state T1 is determined by the onset of the delayed emission spectrum at 77 K, measured in a film of PMMA with 1 to 5 wt.-%, in particular 2 wt.-%, of the emitter and in case of an organic molecule according to the application with 1 to 5 wt.-%, in particular 2 wt.-%, of the organic molecule according to the application, if not stated otherwise. For both host and emitter compounds, the energy of the first excited singlet state S1 is determined by the onset of the emission spectrum, measured in a film of PMMA with 10 wt.-% of the host or emitter compound and in case of an organic molecule according to the application with 1 to 5 wt.-%, in particular 2 wt.-%, of the organic molecule according to the application, if not stated otherwise.

[0533] The onset of the emission spectrum is determined by calculating the intersection of the tangent of the emission spectrum with the x-axis. The tangent of the emission spectrum is set at the high energy side of the emission band and at the point of half maximum of the maximum intensity of the emission spectrum.

[0534] A further aspect of the application relates to the use of an organic molecule according to the application in an optoelectronic device as luminescent emitter or as absorber and / or as host material and / or as electron transport material and / or as hole injection material and / or as hole blocking material.

[0535] A preferred embodiment relates to the use of an organic molecule according to the application in an optoelectronic device as luminescent emitter.

[0536] An optoelectronic device can be understood in the broadest sense as any device based on organic materials that emits or detects electromagnetic radiation in the infrared, visible, or ultraviolet range, or that converts electromagnetic radiation in the infrared, visible, or ultraviolet range into another form of energy or vice versa. Optoelectronic devices can especially be selected from the group consisting of organic light emitting diodes (OLEDs), organic light emitting transistors (OLETs), organic integrated circuits (O-ICs), organic field effect transistors (OFETs), organic thin film transistors (OTFTs), organic light detecting diodes (O-LEDs), solar cells or backplanes of displays.

[0537] In the context of this application, optoelectronic devices are more specifically selected from the group consisting of:

[0538] • Organic light emitting diodes (OLEDs);

[0539] • Light emitting electrochemical cells;

[0540] • OLED sensors, in particular gas and vapor sensors that are not sealed off from the ambient environment;

[0541] • Organic diodes;

[0542] • Organic solar cells;

[0543] • Organic transistors;

[0544] • Organic field effect transistors;

[0545] • Organic lasers; and

[0546] • Down-conversion elements.

[0547] In a preferred embodiment in the context of this application, the optoelectronic device is a device selected from the group consisting of organic light emitting diodes (OLEDs), light emitting electrochemical cells (LECs) and light emitting transistors.

[0548] In the context of this application, the fraction of the organic molecules according to the application in the emission layer in the optoelectronic device (more specifically, in the OLED) is 0.1 to 99 wt.-% (more specifically, 1 to 80 wt.-%). In an alternative embodiment, the proportion of the organic molecules in the emission layer is 100 wt.-%.

[0549] In one embodiment, the light emitting layer (also referred to as “emission layer”) not only comprises the organic molecules according to the application, but also a host material whose triplet (T1) and singlet (S1) energy levels are higher in energy than those of the organic molecules.

[0550] Yet another aspect of the application relates to a composition comprising or consisting of:

[0551] (a) at least one organic molecule according to the application, in particular in the form of an emitter and / or a host; and

[0552] (b) one or more emitter and / or host materials different from the organic molecules according to the application; and

[0553] (c) optionally, one or more dyes and / or one or more solvents.

[0554] In one embodiment, the light emitting layer comprises (or consists essentially of) a composition comprising or consisting of:

[0555] (a) at least one organic molecule according to the application, in particular in the form of an emitter and / or a host; and

[0556] (b) one or more emitter and / or host materials different from the organic molecule according to the application; and

[0557] (c) optionally, one or more dyes and / or one or more solvents.

[0558] In particular embodiments, the light-emitting layer (EML) comprises (or consists essentially of) a composition comprising or consisting of:

[0559] (i) 0.1 to 10 wt.-% (preferably, 0.5 to 5 wt.-%, in particular 1 to 3 wt.-%) of one or more organic molecules (E) according to the application;

[0560] (ii) 5 to 99 wt.-% (preferably, 15 to 85 wt.-%, in particular 20 to 75 wt.-%) of at least one host compound (H); and

[0561] (iii) 0.9 to 94.9 wt.-% (preferably, 14.5 to 80 wt.-%, in particular 24 to 77 wt.-%) of at least one further host compound (D) having a structure different from the structure of the organic molecule according to the application; and

[0562] (iv) optionally, 0 to 94 wt.-% (preferably, 0 to 65 wt.-%, in particular 0 to 50 wt.-%) of a solvent; and

[0563] (v) optionally, 0 to 30 wt.-% (in particular, 0 to 20 wt.-%, preferably 0 to 5 wt.-%) of at least one further emitter molecule (F) having a structure different from the structure of the organic molecule according to the application.

[0564] Preferably, energy can be transferred from the host compound (H) to the one or more organic molecules according to the application, in particular, energy can be transferred from the first excited triplet state of the host compound (T1(H)) to the first excited triplet state of the one or more organic molecules according to the application (T1(E)), and / or from the first excited singlet state of the host compound (S1(H)) to the first excited singlet state of the one or more organic molecules according to the application (S1(E)).

[0565] In one embodiment, the host compound (H) has a highest occupied molecular orbital (HOMO(H)) having an energy (E HOMO (H)) and at least one further host compound (D) has a highest occupied molecular orbital (HOMO(D)) having an energy (E HOMO (D)) with E HOMO (H) > E HOMO (D).

[0566] In a further embodiment, the host compound (H) has a lowest unoccupied molecular orbital (LUMO(H)) having an energy (E LUMO (H)) and at least one further host compound (D) has a lowest unoccupied molecular orbital (LUMO(D)) having an energy (E LUMO (D)) with E LUMO (H) > E LUMO (D).

[0567] In one embodiment, the host compound (H) has a highest occupied molecular orbital (HOMO(H)) having an energy (E HOMO (H)) and a lowest unoccupied molecular orbital (LUMO(H)) having an energy (E LUMO (H)) and

[0568] at least one further host compound (D) has a highest occupied molecular orbital (HOMO(D)) having an energy (E HOMO (D)) and a lowest unoccupied molecular orbital (LUMO(D)) having an energy (E LUMO (D),

[0569] The inventive organic molecule (E) has a highest occupied molecular orbital (HOMO(E)) having an energy (E HOMO (E)) and a lowest unoccupied molecular orbital (LUMO(E)) having an energy (E LUMO (E),

[0570] wherein

[0571] E HOMO (H) > E HOMO (D) and the energy level (E HOMO (E)) of the highest occupied molecular orbital (HOMO(E)) of the inventive organic molecule (E) is higher than the energy level (E HOMO (HOMO(H)) of the host compound (H).The difference between (H)) is between -0.5 eV and 0.5 eV (more preferably between -0.3 eV and 0.3 eV, even more preferably between -0.2 eV and 0.2 eV, or even between -0.1 eV and 0.1 eV); and

[0572] E LUMO (H)>E LUMO (D), and according to the invention, the energy level (E) of the lowest unoccupied molecular orbital (LUMO(E)) of the organic molecule (E) LUMO (E)) and the energy level of at least one other host compound D's lowest unoccupied molecular orbital (LUMO(D)) (E) LUMO The difference between (D) is between -0.5 eV and 0.5 eV (more preferably between -0.3 eV and 0.3 eV, even more preferably between -0.2 eV and 0.2 eV, or even between -0.1 eV and 0.1 eV).

[0573] In one embodiment of the invention, the host compound (D) and / or the host compound (H) are thermally activated delayed fluorescence (TADF) materials. TADF materials exhibit fluorescence intensity less than 2500 cm⁻¹. -1 The energy difference ΔE between the first excited singlet state (S1) and the first excited triplet state (T1) corresponds to ΔE ST Value. Preferably, the TADF material exhibits a value of less than 3000 cm. -1 More preferably less than 1500cm -1 or even more preferably less than 1000cm -1 Or even less than 500cm -1 ΔE ST value.

[0574] In one embodiment, the host compound (D) is a TADF material, and the host compound (H) exhibits a length greater than 2500 cm⁻¹. -1 ΔE ST Value. In a specific embodiment, the host compound (D) is a TADF material, and the host compound (H) is selected from the group consisting of CBP, mCP, mCBP, 9-[3-(dibenzofuran-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzothiophen-2-yl)phenyl]-9H-carbazole, 9-[3,5-bis(2-dibenzofuranyl)phenyl]-9H-carbazole and 9-[3,5-bis(2-dibenzothiophenyl)phenyl]-9H-carbazole.

[0575] In one embodiment, the host compound (H) is a TADF material, and the host compound (D) exhibits a thickness greater than 2500 cm⁻¹. -1 ΔE STIn a particular embodiment, the host compound (H) is a TADF material and the host compound (D) is selected from the group consisting of T2T (2,4,6-tris(diphenyl-3-yl)-1,3,5-triazine), T3T (2,4,6-tris(triphenyl-3-yl)-1,3,5-triazine) and / or TST (2,4,6-tris(9,9'-spirobifluorene-2-yl)-1,3,5-triazine).

[0576] In a further aspect, the invention relates to an optoelectronic device comprising an organic molecule as described herein or a composition of matter of the type described herein, more specifically in the form of a device selected from the group consisting of an organic light emitting diode (OLED), a light emitting electrochemical cell, an OLED sensor (more specifically, a gas and vapor sensor that is not hermetically externally isolated), an organic diode, an organic solar cell, an organic transistor, an organic field effect transistor, an organic laser and a down-conversion element.

[0577] In a preferred embodiment, the optoelectronic device is a device selected from the group consisting of an organic light emitting diode (OLED), a light emitting electrochemical cell (LEC) and a light emitting transistor.

[0578] In one embodiment of the inventive optoelectronic device, the organic molecule (E) according to the invention is used as an emitting material in an emitting layer (EML).

[0579] In one embodiment of the inventive optoelectronic device, the emitting layer (EML) consists of a composition according to the invention as described herein.

[0580] When the optoelectronic device is an OLED, it may, for example, have the following layer structure:

[0581] 1. Substrate

[0582] 2. Anode layer, A

[0583] 3. Hole injection layer, HIL

[0584] 4. Hole transport layer, HTL

[0585] 5. Electron blocking layer, EBL

[0586] 6. Emitting layer, EML

[0587] 7. Hole blocking layer, HBL

[0588] 8. Electron transport layer, ETL

[0589] 9. Electron injection layer, EIL

[0590] 10. Cathode layer, C,

[0591] wherein the OLED comprises each layer selected from the group of HIL, HTL, EBL, HBL, ETL, and EIL, optionally only different layers can be merged, the OLED can comprise more than one layer of each layer type defined above.

[0592] Further, in one embodiment, the optoelectronic device can include one or more protective layers that protect the device from damage from exposure to harmful substances in the environment, including, for example, moisture, vapor, and / or gases.

[0593] In one embodiment of the invention, the optoelectronic device is an OLED having the following inverted layer structure:

[0594] 1. Substrate

[0595] 2. Cathode layer, C

[0596] 3. Electron injection layer, EIL

[0597] 4. Electron transport layer, ETL

[0598] 5. Hole blocking layer, HBL

[0599] 6. Emission layer, EML

[0600] 7. Electron blocking layer, EBL

[0601] 8. Hole transport layer, HTL

[0602] 9. Hole injection layer, HIL

[0603] 10. Anode layer, A,

[0604] wherein the OLED comprises each layer selected from the group of HIL, HTL, EBL, HBL, ETL, and EIL, optionally only different layers can be merged, the OLED can comprise more than one layer of each layer type defined above.

[0605] In one embodiment of the invention, the optoelectronic device is an OLED that can have a stacked architecture. In such an architecture, individual cells are stacked on top of one another as opposed to the typical arrangement where OLEDs are placed side by side. An OLED exhibiting a stacked architecture can produce mixed light, specifically, white light can be produced by stacking a blue OLED, a green OLED, and a red OLED. Further, an OLED exhibiting a stacked architecture can include a charge generation layer (CGL) that is typically positioned between two OLED sub-cells and is typically composed of an n-doped layer and a p-doped layer and the n-doped layer of one CGL is typically positioned close to the anode layer.

[0606] In one embodiment of the invention, the optoelectronic device is an OLED comprising two or more emission layers between an anode and a cathode. In particular, such a so-called tandem OLED comprises three emission layers, wherein one emission layer emits red light, one emission layer emits green light, and one emission layer emits blue light, and optionally can further comprise layers such as charge generation layers, blocking layers or transport layers between the individual emission layers. In a further embodiment, the emission layers are stacked adjacently. In a further embodiment, the tandem OLED comprises a charge generation layer between each two emission layers. Additionally, adjacent emission layers or emission layers separated by a charge generation layer can be combined.

[0607] The substrate can be formed of any material or combination of materials. Most commonly, a glass slide is used as the substrate. Alternatively, a thin metal layer (e.g. a copper, gold, silver or aluminium film) or a plastic film or slide can be used. This can allow a higher degree of flexibility. The anode layer (A) is mainly composed of a material which allows to obtain a (substantially) transparent film. Since at least one of the two electrodes should be (substantially) transparent to allow light to be emitted from the OLED, either the anode layer (A) or the cathode layer (C) is transparent. Preferably, the anode layer (A) comprises a large amount of, or even consists of, a transparent conductive oxide (TCO). Such an anode layer (A) can for example comprise indium tin oxide, aluminium zinc oxide, fluorine-doped tin oxide, indium zinc oxide, PbO, SnO, zirconium oxide, molybdenum oxide, vanadium oxide, tungsten oxide, graphite, doped Si, doped Ge, doped GaAs, doped polyaniline, doped polypyrrole and / or doped polythiophene.

[0608] The anode layer (A) can (substantially) consist of indium tin oxide (ITO) (e.g. (In03) 80% - (Sn02) 20%). 0.9 (Sn02) 0.1) composition. The roughness of the anode layer (A) caused by the transparent conductive oxide (TCO) can be compensated by using a hole injection layer (HIL). Furthermore, the HIL can facilitate the injection of quasi-charge carriers (i.e., holes) because the transport of quasi-charge carriers from the TCO to the hole transport layer (HTL) is facilitated. The hole injection layer (HIL) can include poly(3,4-ethylenedioxythiophene) (PEDOT), polystyrene sulfonate (PSS), Mo02, V205, CuPC, or Cul (in particular, a mixture of PEDOT and PSS). The hole injection layer (HIL) can also prevent the diffusion of metal from the anode layer (A) into the hole transport layer (HTL). The HIL can include, for example, PEDOT:PSS (poly(3,4-ethylenedioxythiophene):polystyrene sulfonate), PEDOT (poly(3,4-ethylenedioxythiophene)), mMTDATA (4,4',4"-tris[phenyl(m-tolyl)amino]triphenylamine), Spiro-TAD (2,2',7,7'-tetrakis(n,n-diphenylamino)-9,9'-spirobifluorene), DNTPD (N1,N1'-(biphenyl-4,4'-diyl)bis(N1-phenyl-N4,N4-di-m-tolylbenzene-1,4-diamine)), NPB (N,N'-bis(1-naphthyl)-N,N'-bis-phenyl-(1,1'-biphenyl)-4,4'-diamine), NPNPB (N,N'-diphenyl-N,N'-di-[4-(N,N-diphenyl-amino)phenyl]phenylamine), MeO-TPD (N,N,N',N'-tetra(4-methoxyphenyl)phenylamine), HAT-CN (2,3,6,7,10,11-hexacyano-1,4,5,8,9,12-hexaazatriphenylene), and / or Spiro-NPD (N,N'-diphenyl-N,N'-bis(1-naphthyl)-9,9'-spirobifluorene-2,7-diamine).

[0609] Adjacent to the anode layer (A) or the hole injection layer (HIL), typically a hole transport layer (HTL) is positioned. Here, any hole transport compound can be used. For example, electron-rich heteroaromatic compounds such as triarylamines and / or carbazoles can be used as hole transport compounds. The HTL can lower the energy barrier between the anode layer (A) and the emission layer (EML). The hole transport layer (HTL) can also be an electron blocking layer (EBL). Preferably, the hole transport compound has a rather high energy level of its triplet state T1. For example, the hole transport layer (HTL) can comprise star-shaped heterocycles such as tris(4-carbazoyl-9-ylphenyl)amine (TCTA), poly-TPD (poly(4-butylphenyl-diphenyl-amine)), a-NPD (2,2'-dimethyl-N,N'-di-[(1-naphthyl)-N,N'-diphenyl]-1,1'-biphenyl-4,4'-diamine), TAPC (4,4'-cyclohexyl-diphenyl-[4-(phenyl-phenyl-amino)-phenyl]-amine), 2-TNATA (4,4',4"-tris[2-naphthyl(phenyl)amino]triphenylamine), Spiro-TAD, DNTPD, NPB, NPNPB, MeO-TPD, HAT-CN, and / or Tris-Pcz (9,9'-diphenyl-6-(9-phenyl-9H-carbazol-3-yl)-9H,9'H-3,3'-bicarbazole). Additionally, the HTL can comprise a p-doped layer which can consist of inorganic or organic dopants in an organic hole transport matrix. Transition metal oxides such as vanadium oxide, molybdenum oxide or tungsten oxide can for example be used as inorganic dopants. Tetrafluorotetracyanoquinodimethane (F4-TCNQ), copper pentafluorobenzoate (Cu(I) pFBz) or transition metal complexes can for example be used as organic dopants.

[0610] The EBL can for example comprise mCP (1,3-bis(carbazol-9-yl)benzene), TCTA, 2-TNATA, mCBP (3,3-di(9H-carbazol-9-yl)biphenyl), Tris-Pcz, CzSi (9-(4-tert-butylphenyl)-3,6-bis(triphenylsilyl)-9H-carbazole), and / or DCB (N,N'-dicarbazolyl-1,4-dimethylbenzene).

[0611] Adjacent to the hole transport layer (HTL), typically a light-emitting layer (EML) is positioned. The light-emitting layer (EML) comprises at least one organic molecule. Specifically, the EML comprises at least one organic molecule (E) according to the invention. In one embodiment, the light-emitting layer comprises only organic molecules according to the invention. Typically, the EML additionally comprises one or more host materials (H). For example, the host material (H) is selected from CBP (4,4'-bis(N-carbazolyl)biphenyl), mCP, mCBP, Sif87 (dibenzo[b,d]thiophene-2-yltriphenylsilane), CzSi, Sif88 (dibenzo[b,d]thiophene-2- yldiphenylsilane), DPEPO (bis[2-(diphenylphosphino)phenyl]ether oxide), 9-[3-(dibenzo- furan-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzo-thiophene-2-yl)phenyl]-9H-carbazole, 9-[3,5- bis(2-dibenzo-furan-yl)phenyl]-9H-carbazole, 9-[3,5-bis(2-dibenzo-thiophene-yl)phenyl]-9H- carbazole, T2T (2,4,6-tris(biphenyl-3-yl)-1,3,5-triazine), T3T (2,4,6-tris(terphenyl-3-yl)-1,3,5- triazine) and / or TST (2,4,6-tris(9,9'-spirobifluorene-2-yl)-1,3,5-triazine). The host material (H) should typically be selected to exhibit a first triplet (T1 ) and a first singlet (S1 ) energy level energetically higher than the first triplet (T1 ) and the first singlet (S1 ) energy level of the organic molecule.

[0612] In one embodiment of the application, the EML comprises a so-called mixed host system with at least one hole-dominant host and one electron-dominant host. In a specific embodiment, the EML comprises exactly one organic molecule according to the application and a mixed host system comprising T2T as electron-dominant host and a host selected from CBP, mCP, mCBP, 9-[3-(dibenzofuran-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzothiophene-2-yl)phenyl]-9H-carbazole, 9-[3,5-bis(2-dibenzofuranyl)phenyl]-9H-carbazole and 9-[3,5-bis(2-dibenzothiophenyl)phenyl]-9H-carbazole as hole-dominant host. In a further embodiment, the EML comprises 50 to 80 wt.-% (preferably 60 to 75 wt.-%) of a host selected from CBP, mCP, mCBP, 9-[3-(dibenzofuran-2-yl)phenyl]-9H-carbazole, 9-[3-(dibenzothiophene-2-yl)phenyl]-9H-carbazole, 9-[3,5-bis(2-dibenzofuranyl)phenyl]-9H-carbazole and 9-[3,5-bis(2-dibenzothiophenyl)phenyl]-9H-carbazole, 10 to 45 wt.-% (preferably 15 to 30 wt.-%) of T2T and 5 to 40 wt.-% (preferably 10 to 30 wt.-%) of the organic molecule according to the application.

[0613] Adjacent to the light-emitting layer (EML), an electron-transporting layer (ETL) can be positioned. Here, any electron-transporting agent can be used. Illustratively, electron-impoverished compounds such as benzimidazoles, pyridines, triazoles, oxadiazoles (e.g., 1,3,4-oxadiazole), phosphine oxides and sulfones can be used. The electron-transporting body can also be a star-shaped heterocycle such as 1,3,5-tris(1-phenyl-1H-benzo[d]imidazol-2-yl)benzene (TPBi). The ETL can comprise NBphen (2,9-bis(naphthalen-2-yl)-4,7-diphenyl-1,10-phenanthroline), Alq3 (tris(8-hydroxyquinoline)aluminum), TSPO1 (diphenyl-4-triphenylsilylphenyl-phosphine oxide), BPyTP2 (2,7-bis(2,2'-bipyridin-5-yl)triphenylene), Sif87 (dibenzo[b,d]thiophene-2-yltriphenylsilane), Sif88 (dibenzo[b,d]thiophene-2-yl-diphenylsilane), BmPyPhB (1,3-bis[3,5-di(pyridin-3-yl)phenyl]benzene) and / or BTB (4,4'-bis[2-(4,6-diphenyl-1,3,5-triazinyl)]-1,1'-biphenyl). Optionally, the ETL can be doped with a material such as Liq. The electron-transporting layer (ETL) can also block holes, or a hole-blocking layer (HBL) is introduced.

[0614] The HBL can for example comprise BCP (2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline = bathocuproin), BAIq (bis(8-hydroxy-2-methylquinoline)-(4- phenylphenoxy)aluminum), NBphen (2,9-bis(naphthalen-2-yl)-4,7-diphenyl- 1,10-phenanthroline), AIq3 (tris(8-hydroxyquinoline)aluminum), TSPO1 (diphenyl-4-triphenylsilylphenyl-phosphine oxide), T2T (2,4,6-tris(biphenyl-3-yl)- 1,3,5-triazine), T3T (2,4,6-tris(triphenyl-3-yl)-1,3,5-triazine), TST (2,4,6-tris(9,9'- spirobifluorene-2-yl)-1,3,5-triazine) and / or TCB / TCP (1,3,5-tri(N-carbazolyl)benzene / 1,3,5-tri(carbazol-9-yl)benzene).

[0615] Adjacent to the electron transport layer (ETL), a cathode layer (C) can be positioned. The cathode layer (C) can for example comprise or consist of a metal (e.g. Al, Au, Ag, Pt, Cu, Zn, Ni, Fe, Pb, LiF, Ca, Ba, Mg, In, W or Pd) or a metal alloy. For practical reasons, the cathode layer can also consist of a (substantially) non-transparent metal such as Mg, Ca or Al. Optionally or additionally, the cathode layer (C) can also comprise graphite and / or carbon nanotubes (CNT). Optionally, the cathode layer (C) can also consist of nanoscale silver wires.

[0616] The OLED can further optionally comprise a protective layer between the electron transport layer (ETL) and the cathode layer (C) (which can be designated as electron injection layer (EIL)). This layer can comprise lithium fluoride, cesium fluoride, silver, Liq (lithium 8-hydroxyquinolate), Li2O, BaF2, MgO and / or NaF.

[0617] Optionally, the electron transport layer (ETL) and / or the hole blocking layer (HBL) can also comprise one or more host compounds (H).

[0618] For further modifying the emission spectrum and / or the absorption spectrum of the light-emitting layer (EML), the light-emitting layer EML can further comprise one or more further emitter molecules (F). Such emitter molecules (F) can be any emitter molecule known in the art. Preferably, such emitter molecules (F) are molecules having a structure different from the structure of the organic molecules (E) according to the application. The emitter molecules (F) can optionally be TADF emitters. Optionally, the emitter molecules (F) can optionally be fluorescent and / or phosphorescent emitter molecules capable of shifting the emission spectrum and / or the absorption spectrum of the light-emitting layer (EML). Exemplarily, by emitting light typically red-shifted compared to the light emitted by the organic molecules, triplet and / or singlet excitons can be transferred from the organic molecules according to the application to the emitter molecules (F) before relaxing to the ground state (S0). Optionally, the emitter molecules (F) can also cause a two-photon effect (i.e. the absorption of two photons for the energy of half of the absorption maximum).

[0619] Optionally, the optoelectronic device (e.g. OLED) can for example be a substantially white optoelectronic device. For example, such white optoelectronic device can comprise at least one (deep) blue emitter molecule and one or more emitter molecules emitting green and / or red light. Then, energy transmittance can also optionally exist between two or more molecules as described above.

[0620] As used herein, the designation of the color of emitted and / or absorbed light is as follows, if not more specifically defined in the particular context:

[0621] Violet: wavelength range > 380 nm to 420 nm;

[0622] Deep blue: wavelength range > 420 nm to 480 nm;

[0623] Sky blue: wavelength range > 480 nm to 500 nm;

[0624] Green: wavelength range > 500 nm to 560 nm;

[0625] Yellow: wavelength range > 560 nm to 580 nm;

[0626] Orange: wavelength range > 580 nm to 620 nm;

[0627] Red: wavelength range > 620 nm to 800 nm.

[0628] For emitter molecules, this color refers to the emission maximum. Thus, for example, a deep blue emitter has an emission maximum in the range of > 420 nm to 480 nm, a sky blue emitter has an emission maximum in the range of > 480 nm to 500 nm, a green emitter has an emission maximum in the range of > 500 nm to 560 nm, and a red emitter has an emission maximum in the range of > 620 nm to 800 nm.

[0629] A deep blue emitter can preferably have an emission maximum below 480 nm, more preferably below 470 nm, even more preferably below 465 nm or even below 460 nm. It will typically be above 420 nm, preferably above 430 nm, more preferably above 440 nm or even above 450 nm.

[0630] A green emitter has an emission maximum below 560 nm, more preferably below 550 nm, even more preferably below 545 nm or even below 540 nm. It will typically be above 500 nm, more preferably above 510 nm, even more preferably above 515 nm or even above 520 nm.

[0631] Thus, a further aspect of the present application relates to an OLED which exhibits an external quantum efficiency of more than 8% (more preferably more than 10%, more preferably more than 13%, even more preferably more than 15% or even more than 20%) at 1000 cd / m 2 and / or exhibits an emission maximum between 420 nm and 500 nm (preferably between 430 nm and 490 nm, more preferably between 440 nm and 480 nm, even more preferably between 450 nm and 470 nm) and / or exhibits an LT80 value of more than 100 hours (preferably more than 200 hours, more preferably more than 400 hours, even more preferably more than 750 hours or even more than 1000 hours) at 500 cd / m 2 Thus, a further aspect of the present application relates to an OLED whose emission exhibits a CIEy color coordinate of less than 0.45 (preferably less than 0.30, more preferably less than 0.20 or even more preferably less than 0.15 or even less than 0.10).

[0632] Yet another aspect of the present application relates to an OLED emitting light at different color points. According to the present application, the OLED emits light having a narrow emission band (small full width at half maximum (FWHM)). In one aspect, the OLED according to the application emits light having a FWHM of the main emission peak of less than 0.25 eV (preferably less than 0.20 eV, more preferably less than 0.17 eV, even more preferably less than 0.15 eV, or even less than 0.13 eV).

[0633] Yet another aspect of the present application relates to an OLED emitting light having CIEx and CIEy color coordinates (CIEx = 0.131, CIEy = 0.046) close to the CIEx (= 0.131 ) and CIEy (= 0.046) color coordinates of the primary color blue as defined by ITU-R Recommendation BT.2020 (Rec. 2020), and thus suitable for application in Ultra High Definition (UHD) displays (e.g. UHD-TV). Thus, yet another aspect of the present application relates to an OLED whose emission exhibits CIEx color coordinates between 0.02 and 0.30 (preferably between 0.03 and 0.25, more preferably between 0.05 and 0.20, or even more preferably between 0.08 and 0.18, or even between 0.10 and 0.15) and / or CIEy color coordinates between 0.00 and 0.45 (preferably between 0.01 and 0.30, more preferably between 0.02 and 0.20, or even more preferably between 0.03 and 0.15, or even between 0.04 and 0.10).

[0634] Another embodiment of the present application relates to an OLED which emits light having CIEx and CIEy color coordinates (CIEx = 0.170, CIEy = 0.797) which are close to the CIEx (= 0.170) and CIEy (= 0.797) color coordinates of the primary color green as defined by ITU-R Recommendation BT.2020 (Rec. 2020) and thus suitable for application in Ultra High Definition (UHD) displays (e.g. UHD-TV). In this context, the term "close to" refers to the range of CIEx and CIEy coordinates provided at the end of this paragraph. In commercial applications, typically top-emitting (the top electrode is transparent) devices are used, while the test devices used throughout this application represent bottom-emitting devices (the bottom electrode and the substrate are transparent). Thus, yet another aspect of the present application relates to an OLED whose emission exhibits CIEx color coordinates between 0.15 and 0.45 (preferably between 0.15 and 0.35, more preferably between 0.15 and 0.30, or even more preferably between 0.15 and 0.25, or even between 0.15 and 0.20) and / or CIEy color coordinates between 0.60 and 0.92 (preferably between 0.65 and 0.90, more preferably between 0.70 and 0.88, or even more preferably between 0.75 and 0.86, or even between 0.79 and 0.84).

[0635] Thus, yet another aspect of the present application relates to an OLED which exhibits an external quantum efficiency of more than 8% (more preferably more than 10%, more preferably more than 13%, even more preferably more than 15%, or even more than 17%, or even more than 20%) at 14500 cd / m 2 and / or exhibits an emission maximum between 485 nm and 560 nm (preferably between 500 nm and 560 nm, more preferably between 510 nm and 550 nm, even more preferably between 515 nm and 540 nm) and / or exhibits an LT97 value of more than 100 hours (preferably more than 250 hours, more preferably more than 500 hours, even more preferably more than 750 hours, or even more than 1000 hours). 2 and / or exhibits an emission maximum between 485 nm and 560 nm (preferably between 500 nm and 560 nm, more preferably between 510 nm and 550 nm, even more preferably between 515 nm and 540 nm) and / or exhibits an LT97 value of more than 100 hours (preferably more than 250 hours, more preferably more than 500 hours, even more preferably more than 750 hours, or even more than 1000 hours).

[0636] In yet another embodiment of the present application, the composition has a photoluminescence quantum yield (PLQY) of more than 20% (preferably more than 30%, more preferably more than 35%, more preferably more than 40%, more preferably more than 45%, more preferably more than 50%, more preferably more than 55%, even more preferably more than 60%, or even more than 70%) at room temperature.

[0637] In yet another aspect, the invention relates to a method for fabricating an optoelectronic component. In this case, the inventive organic molecules are used.

[0638] The optoelectronic devices according to the present application (in particular OLEDs) can be fabricated by any means of gas phase deposition and / or liquid handling. Thus, at least one layer:

[0639] - is prepared by way of a sublimation process,

[0640] - is prepared by way of an organic vapour phase deposition process,

[0641] - is prepared by way of a carrier gas sublimation process,

[0642] - is solution-processed or printed.

[0643] The method for fabricating optoelectronic devices (in particular OLEDs) according to the present application is known in the art. By way of subsequent deposition processes, different layers are deposited individually and successively on a suitable substrate. The individual layers can be deposited using the same or different deposition methods.

[0644] Gas phase deposition processes include, for example, thermal (co-)evaporation, chemical vapour deposition and physical vapour deposition. For active matrix OLED displays, an AMOLED backplane is used as a substrate. The individual layers can be processed from solutions or dispersions using appropriate solvents. Solution deposition processes include, for example, spin coating, dip coating and jet printing. Liquid handling can optionally be carried out in an inert atmosphere (for example, in a nitrogen atmosphere), and the solvent can be completely or partially removed by means known in the art.

[0645] Examples

[0646] General synthesis scheme I

[0647]

[0648] General synthesis scheme II

[0649]

[0650] General procedure for synthesis:

[0651] AAV1 : I0 (1.00 equiv), 3,5-dichloro-iodobenzene (10-1, 0.8 equiv), palladium(II) acetate (0.03 equiv), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (SPhos, CAS: 657408-07-6, 0.06 equiv) and potassium phosphate tribasic (K3PO4; 3.00 equiv) were stirred in a dioxane / water mixture at 90 °C under nitrogen atmosphere for 12 h. After cooling to room temperature (rt), the reaction mixture was extracted between DCM and brine and the phases were separated, then the solvent was removed under reduced pressure. The crude material was purified by column chromatography to obtain 1-1 in 84% yield. GC-MS: 313.02 m / z.

[0652] AAV2: 1-1 (1.00 equiv), diphenylamine (CAS: 122-39-4, 2.5 equiv), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.01 equiv), tri-tert-butylphosphine (CAS: 13716-12-6, 0.04 equiv) and sodium tert-butoxide (CAS: 865-48-5, 4.00 equiv) were stirred in anhydrous toluene at 100 °C under nitrogen atmosphere for 12 h. After cooling to room temperature (rt), the reaction mixture was washed with water and brine and the phases were separated, then the solvent was removed under reduced pressure. The crude material was purified by recrystallization to obtain 1-2 in 45% yield. LC-MS: 578.40 m / z, rt (retention time) at: 4.69 min.

[0653] AAV3: 1-2 (1.00 equiv) was placed in a round bottom flask under nitrogen. Solvent 1,2-dichlorobenzene was added. Boron tribromide (CAS: 10294-33-4, 6.00 equiv) was added dropwise and heated to 180 °C. After cooling to rt, it was further cooled to 0 °C. DIPEA (CAS: 7087-68-5, 10.00 equiv) was added and stirred for 1 h. The reaction mixture was washed with water and the phases were separated, then the solvent was removed under reduced pressure. The crude material was purified by column chromatography to obtain P in 32% yield. LC-MS: 586 m / z, rt at: 5.73 min.

[0654] General synthesis scheme III

[0655]

[0656] General procedure for synthesis:

[0657] AAV4: E1 (1.00 eq), bis(pinacolato)diboron (CAS: 73183-34-3, 1.0 eq), tris(dibenzylideneacetone)dipalladium (CAS: 51364-51-3, 0.02 eq), 2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'- biphenyl (X-Phos, CAS: 564483-18-7, 0.08 eq) and potassium acetate (KOAc, CAS: 127-08-2, 2.00 eq) were stirred in anhydrous toluene at 105 °C under nitrogen atmosphere for 24 h. After cooling to room temperature (rt), the reaction mixture was extracted between ethyl acetate and brine and the combined organic layers were concentrated under reduced pressure. The crude material was purified by column chromatography or by recrystallization to afford I-4 as a solid.

[0658] AAV5: I-4 (1.00 eq), E2 (1.0 eq), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.01 eq), SPhos (CAS: 657408-07-6, 0.04 eq) and potassium phosphate tribasic (K3PO4, CAS: 7778-53-2, 3.00 eq) were stirred in a dioxane / water mixture at 100 °C for 2 h. After cooling to room temperature (rt), the reaction mixture was washed with water and brine. The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude material was purified by recrystallization or column chromatography to afford I-5 as a solid.

[0659] AAV6: I-5 (1.00 eq) was taken in a round bottom flask under nitrogen. Solvent 1,2- dichlorobenzene was added. Boron tribromide (CAS: 10294-33-4, 4.00 eq) was added dropwise and heated to 180 °C overnight. After cooling to rt, it was further cooled to 0 °C. DIPEA (CAS: 7087-68-5, 10.00 eq) was added and stirred for 1 h. The reaction mixture was washed with water and the phases were separated, then the solvent was removed under reduced pressure. The crude material was purified by column chromatography or by recrystallization to afford P-1 as a solid.

[0660] General synthesis scheme IV

[0661]

[0662] General procedure for synthesis:

[0663] AAV7: Stir E3 (2.00 eq), E4 (1.0 eq), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.01 eq), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (SPhos, CAS: 657408-07-6, 0.04 eq) and potassium phosphate tribasic (K3PO4, 3.00 eq) in a THF / water mixture at 80 °C under nitrogen atmosphere. After cooling to room temperature (rt), extract the reaction mixture between ethyl acetate and brine and separate the phases, then remove the solvent under reduced pressure. Purify the crude material by column chromatography or by recrystallization to obtain I-6 as a solid.

[0664] AAV8: Stir I-6 (1.00 eq), E5 (1.00 eq), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.01 eq), tri-tert-butylphosphine (CAS: 13716-12-6, 0.04 eq) and sodium tert-butoxide (CAS: 865-48-5, 3.00 eq) in anhydrous toluene at 110 °C for 72 h under nitrogen atmosphere. After cooling to room temperature (rt), wash the reaction mixture with water and brine and separate the phases, then remove the solvent under reduced pressure. Purify the crude material by recrystallization or column chromatography to obtain I-7 as a solid.

[0665] AAV9: Place I-7 (1.00 eq) in a round bottom flask under nitrogen. Add solvent 1,2-dichlorobenzene. Add boron tribromide (CAS: 10294-33-4, 4.00 eq) dropwise and heat it to 180 °C. After cooling to rt, further cool it to 0 °C. Add DIPEA (CAS: 7087-68-5, 10.00 eq) and stir it for 1 h. Wash the reaction mixture with water and separate the phases, then remove the solvent under reduced pressure. Purify the crude material by column chromatography or by recrystallization to obtain P-2 as a solid.

[0666] General synthesis scheme V

[0667]

[0668] General procedure for synthesis:

[0669] AAV10: Stir E5 (1.05 eq), E6 (1.00 eq), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.005 eq), sodium tert-butoxide (NaOtBu, CAS: 865-48-5, 1.50 eq) and tri-tert-butylphosphonium tetrafluoroborate (P(tBu)3HBF4; CAS: 131274-22-1, 0.02 eq) in anhydrous toluene under nitrogen atmosphere at 100 °C overnight. After cooling to room temperature (rt), water is added to the reaction mixture, the phases are separated and the combined organic layers are dried with anhydrous MgS04, filtered and concentrated under reduced pressure. The crude material is purified by column chromatography or by recrystallization to yield I-8 as a solid.

[0670] AAV11: Stir I-8 (1.00 eq), E3 (1.2 eq), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.01 eq), X-Phos (CAS: 564483-18-7, 0.04 eq) and potassium phosphate tribasic (K3P04, CAS: 7778-53-2, 2.00 eq) in a THF / water mixture under nitrogen atmosphere at 80 °C for 96 h. After cooling to room temperature (rt), the reaction mixture is washed with water and brine, the combined organic layers are dried with anhydrous MgS04, filtered and concentrated under reduced pressure. The crude material is purified by recrystallization or column chromatography to yield I-7 as a solid.

[0671] The last reaction step is performed as described in AAV9, wherein 1,2-dichlorobenzene is used as solvent and wherein the reaction temperature is 180 °C.

[0672] General synthesis scheme VI

[0673]

[0674] General procedure for the synthesis:

[0675] The first reaction step is performed as described in AAV7.

[0676] AAV12: Stir I-6 (2.00 eq), E7 (1.0 eq), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.01 eq), tri-tert-butylphosphine (CAS: 13716-12-6, 0.04 eq) and sodium tert-butoxide (CAS: 865-48-5, 6.00 eq) in anhydrous toluene under nitrogen atmosphere at 110 °C for 72 h. After cooling to room temperature (rt), the reaction mixture is extracted between ethyl acetate and brine and the phases are separated and the solvent is removed under reduced pressure. The crude material is purified by recrystallization or by column chromatography to yield I-9 as a solid.

[0677] AAV13: I-9 (1.00 eq) was placed in a round bottom flask under nitrogen. Solvent 1,2-dichlorobenzene was added. Boron tribromide (CAS: 10294-33-4, 6.00 eq) was added dropwise and heated to 180 °C. After cooling to rt, it was further cooled to 0 °C. DIPEA (CAS: 7087-68-5, 10.00 eq) was added and stirred for 1 h. The reaction mixture was washed with water and the phases were separated, then the solvent was removed under reduced pressure. The crude material was purified by column chromatography or recrystallization to obtain P-3 as a solid.

[0678] General synthesis scheme VII

[0679]

[0680] General procedure for synthesis:

[0681] AAV14: E5 (2.10 eq), E8 (1.00 eq), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.01 eq), sodium tert-butoxide (NaOtBu, CAS: 865-48-5, 3.15 eq) and tri-tert-butylphosphine (P(tBu)3; CAS: 13716-12-6, 0.04 eq) were stirred in anhydrous toluene at 110 °C for 1 h under nitrogen atmosphere. After cooling to room temperature (rt), the reaction mixture was extracted between ethyl acetate and brine and the combined organic layers were concentrated under reduced pressure. The crude material was purified by column chromatography or by recrystallization to obtain I-10 as a solid.

[0682] AAV15: I-10 (1.00 eq), E3 (1.2 eq), palladium(II)acetate (CAS: 3375-31-3, 0.06 eq), XPhos (CAS: 564483-18-7, 0.12 eq) and potassium phosphate tribasic (K3PO4, CAS: 7778-53-2, 3.00 eq) were stirred in a dioxane / water mixture at 100 °C for 55 h under nitrogen atmosphere. After cooling to room temperature (rt), the reaction mixture was extracted between toluene and brine and the combined organic layers were concentrated under reduced pressure. The crude material was purified by recrystallization or column chromatography to obtain I-11 as a solid.

[0683] AAV0-3:

[0684] I-11 (1.00 equiv) was dissolved in t-butylbenzene under nitrogen. At 20 °C, n-BuLi (2.5 M in hexane, CAS: 109-72-8, 1.1 equiv) was injected and the mixture was stirred for 15 min. Subsequently, t-BuLi (1 M in pentane, CAS: 594-19-4, 2.2 equiv) was added and the mixture was stirred at 60 °C for 2 hours. Subsequently, the mixture was cooled to below -78 °C, then BBr3(CAS: 10294-33-4, 1.3 equiv) was added dropwise. The mixture was warmed to rt, then stirred at rt for 16 hours. The mixture was extracted between ethyl acetate and water, and the combined organic layers were concentrated under reduced pressure. The crude product was purified with column chromatography or by recrystallization to obtain the target compound P-4 as a solid.

[0685] General synthesis scheme VIII

[0686]

[0687] General procedure for synthesis:

[0688] AAV16: E3 (1.00 equiv), E9 (1.1 equiv), tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4, CAS: 14221-01-3, 0.02 equiv) and potassium carbonate (K2CO3; 2.00 equiv) were stirred in a THF / water mixture at 80 °C under a nitrogen atmosphere for 48 hours. After cooling to room temperature (rt), the phases were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude material was purified by column chromatography or by recrystallization to obtain I-12 as a solid.

[0689] AAV17: I-12 (1.00 equiv), di-tert-butyl dicarbonate (CAS: 24424-99-5, 1.4 equiv), 4-dimethylaminopyridine (4-DMAP, CAS: 1122-58-3, 1.00 equiv) were stirred in anhydrous MeCN at room temperature under a nitrogen atmosphere for 16 hours. NaOH solution (1 M) was added to the reaction mixture, the phases were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude material was purified by column chromatography or by recrystallization to obtain I-13 as a solid.

[0690] AAV18: I-13 (1.00 equiv), E5 (1.20 equiv), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.01 equiv), tri-tert-butylphosphonium tetrafluoroborate (CAS: 131274-22-1, 0.04 equiv) and sodium tert-butoxide (CAS: 865-48-5, 2.00 equiv) were stirred in anhydrous toluene at 110 °C for 16 h under nitrogen atmosphere. After cooling to room temperature (rt), the reaction mixture was washed with water and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over anhydrous MgS04, filtered and concentrated under reduced pressure. The crude material was purified by recrystallization or column chromatography to obtain I-14 as a solid.

[0691] AAV19: I-14 (1.00 equiv) was dissolved in dichloromethane (DCM). Trifluoroacetic acid (CAS: 76-05-1; 99.7 equiv) was added at room temperature and the reaction mixture was stirred for 2 h. Then, the phases were separated and the TFA layer was extracted with DCM. The combined organic layers were washed with saturated NaHC03solution and water, dried over anhydrous MgS04and filtered. After removal of the solvent under reduced pressure, the crude material was purified by recrystallization or column chromatography to obtain I-15 as a solid.

[0692] AAV20: I-15 (1.00 equiv) was placed in a round bottom flask under nitrogen. The solvent o-xylene was added. At 20 °C, n-butyllithium (2.5 M in hexane, CAS: 109-72-8, 1.10 equiv) was added dropwise and the mixture was stirred for 15 min. Then, tert-butyllithium (1.6 M in hexane, CAS: 594-19-4, 2.20 equiv) was added dropwise, the temperature was raised to 60 °C and the reaction mixture was stirred for 2 h. The reaction mixture was cooled to room temperature. At 0 °C, boron tribromide (1 M in heptane, CAS: 10294-33-4, 1.30 equiv) was added dropwise, the mixture was stirred at 0 °C for 1 h and then at rt for 6 h. The reaction mixture was poured into a 5% NH3solution, the phases were separated and the organic layer was washed with water. The organic layer was dried over anhydrous MgS04, filtered and concentrated under reduced pressure. The crude material was purified by column chromatography or by recrystallization to obtain P-5 as a solid.

[0693] General synthesis scheme IX

[0694]

[0695] General procedure for synthesis:

[0696] AAV21 : E10 (1.10 eq), E11 (1.00 eq) and tri-potassium phosphate (1.50 eq, CAS: 7778-53-2) were heated in anhydrous DMSO at 100 °C for 48 h. After cooling to rt, the mixture was poured into ice water. The precipitate was filtered off, washed with water and ethanol and collected. The crude product was purified by recrystallization or column chromatography to obtain compound I-16 as a solid.

[0697] AAV22: I-16 (1.00 eq) was reacted with E3 (1.00 eq), tri-potassium phosphate (1.80 eq, CAS: 7778-53-2), tris(dibenzylideneacetone)dipalladium(0) (0.01 eq, CAS: 51364-51-3) and X-Phos (0.04 eq, CAS: 564483-18-7) in a mixture of toluene / water (8:1 by volume) at 95 °C for 48 h under nitrogen. After cooling to rt, the phases were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over anhydrous MgS04, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography or recrystallization to obtain compound I-17 as a solid.

[0698] AAV23: I-17 (1.00 eq) was reacted with E12 (1.50 eq), tri-potassium phosphate (3.00 eq, CAS: 7778-53-2), tris(dibenzylideneacetone)dipalladium(0) (0.01 eq, CAS: 51364-51-3) and X-Phos (0.04 eq, CAS: 564483-18-7) in a mixture of dioxane / water (5:1 by volume) at 100 °C for 5 h under nitrogen. After cooling to rt, the phases were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over anhydrous MgS04, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography or recrystallization to obtain compound I-18 as a solid.

[0699] The last reaction step was performed as described in AAV20.

[0700] General synthesis scheme X

[0701]

[0702] General procedure for synthesis:

[0703] AAV24: E13 (1.10 eq), E11 (1.00 eq) and tri-potassium phosphate (1.50 eq, CAS: 7778-53-2) were heated in anhydrous DMSO at 100 °C for 48 h. After cooling to rt, the mixture was poured into ice water. The precipitate was filtered off, washed with water and ethanol and collected. The crude product was purified by recrystallization or column chromatography to obtain compound I-19 as a solid.

[0704] AAV25: I-19 (1.00 eq) was reacted with E3 (1.20 eq), tri-potassium phosphate (2.00 eq, CAS: 7778-53-2), tris(dibenzylideneacetone)dipalladium(0) (0.01 eq, CAS: 51364-51-3) and X-Phos (0.04 eq, CAS: 564483-18-7) in a mixture of toluene / water (8:1 by volume) at 100 °C for 5 h under nitrogen. After cooling to rt, the phases were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over anhydrous MgS04, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography or recrystallization to obtain compound I-20 as a solid.

[0705] The last reaction step was performed as described in AAV0-3.

[0706] General synthesis scheme XI

[0707]

[0708] General procedure for synthesis:

[0709] AAV26: E14 (1.00 eq) was reacted with E3 (1.00 eq), potassium carbonate (2.00 eq, CAS: 584-08-7), tris(dibenzylideneacetone)dipalladium(0) (0.02 eq, CAS: 51364-51-3) and S-Phos (0.08 eq, CAS: 657408-07-6) in a mixture of dioxane / water (10:1 by volume) at 90 °C for 72 h under nitrogen. After cooling to rt, the phases were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over anhydrous MgS04, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography or recrystallization to obtain compound I-21 as a solid.

[0710] AAV27: E5 (1.00 equiv), 1-21 (1.00 equiv), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.01 equiv), sodium tert-butoxide (NaOtBu, CAS: 865-48-5, 3.00 equiv) and tri-tert-butylphosphine (P(tBu)3; CAS: 13716-12-6, 0.04 equiv) were stirred in anhydrous toluene at 110 °C for 24 h under nitrogen atmosphere. After cooling to room temperature (rt), the reaction mixture was extracted between ethyl acetate and brine and the combined organic layers were concentrated under reduced pressure. The crude material was purified by column chromatography or by recrystallization to afford 1-22 as a solid.

[0711] AAV28: 1-22 (1.00 equiv) was reacted with BBr3 (3.00 equiv, CAS: 10294-33-4) in anhydrous dichlorobenzene at 135 °C for 45 min under nitrogen. After cooling to rt, the mixture was further cooled to 0 °C before the addition of DIPEA (10.0 equiv, CAS: 7087-68-5). Water was added, the phases were separated and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with water, dried over anhydrous MgS04, filtered and concentrated. The crude product was purified by column chromatography or recrystallization to afford compound P-8 as a solid.

[0712] General synthesis scheme XII

[0713]

[0714] General procedure for synthesis:

[0715] AAV29: E5 (1.05 equiv), E14 (1.00 equiv), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.005 equiv), sodium tert-butoxide (NaOtBu, CAS: 865-48-5, 1.50 equiv) and tri-tert-butylphosphonium tetrafluoroborate (HP(tBu)3BF4; CAS: 131274-22-1, 0.02 equiv) were stirred in anhydrous toluene at 100 °C for 1 h under nitrogen atmosphere. After cooling to room temperature (rt), the reaction mixture was extracted between ethyl acetate and brine and the combined organic layers were concentrated under reduced pressure. The crude material was purified by column chromatography or by recrystallization to afford 1-23 as a solid.

[0716] AAV30: I-23 (1.00 equiv) was reacted with E3 (1.10 equiv), tri-potassium phosphate (2.00 equiv, CAS: 7778-53-2), tris(dibenzylideneacetone)dipalladium(0) (0.01 equiv, CAS: 51364-51-3) and S-Phos (0.04 equiv, CAS: 657408-07-6) in a mixture of dioxane / water (5:1 by volume) at 100 °C for 48 h under nitrogen. After cooling to rt, the phases were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over anhydrous MgS04, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography or recrystallization to obtain compound I-24 as a solid.

[0717] AAV31: I-24 (1.00 equiv) was reacted with BBr3 (3.00 equiv, CAS: 10294-33-4) in anhydrous dichlorobenzene at 90 °C for 1 h under nitrogen. After cooling to rt, the mixture was further cooled to 0 °C before the addition of DIPEA (10.0 equiv, CAS: 7087-68-5). Water was added, the phases were separated, and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with water, dried over anhydrous MgS04, filtered and concentrated. The crude product was purified by column chromatography or recrystallization to obtain compound P-9 as a solid.

[0718] General synthesis scheme XIII

[0719]

[0720] General procedure for synthesis:

[0721] AAV32: E3 (1.00 equiv) was reacted with E9 (1.30 equiv), potassium carbonate (2.00 equiv, CAS: 584-08-7) and tetrakis(triphenylphosphine)palladium(0) (0.03 equiv, CAS: 14221-01-3) in a mixture of dioxane / water (4:1 by volume) at 80 °C for 8 h under nitrogen. After cooling to rt, the phases were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over anhydrous MgS04, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography or recrystallization to obtain compound I-12 as a solid.

[0722] AAV33: E5 (1.10 eq), I-12 (1.00 eq), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.01 eq), sodium tert-butoxide (NaOtBu, CAS: 865-48-5, 3.20 eq) and tri-tert-butylphosphonium tetrafluoroborate (HP(tBu)3BF4; CAS: 131274-22-1, 0.04 eq) were stirred in anhydrous toluene at 110 °C under nitrogen atmosphere for 3 h. After cooling to room temperature (rt), the reaction mixture was extracted between ethyl acetate and brine and the combined organic layers were concentrated under reduced pressure. The crude material was purified by column chromatography or by recrystallization to obtain I-15 as a solid.

[0723] AAV34: To a solution of I-15 (1.00 eq) in anhydrous o-xylene was added n-BuLi (2.5 M in hexanes, 1.10 eq, CAS: 109-72-8) at rt under nitrogen. After stirring for 15 min, t-BuLi (1.6 M in pentane, 2.20 eq, CAS: 594-19-4) was added and the mixture was heated at 60 °C for 2 h. Subsequently, the mixture was cooled to below -60 °C and then BBr3(1.50 eq, CAS: 10294-33-4) was added dropwise. The mixture was then stirred at 0 °C for 1 h and then at rt for 16 h. The mixture was poured into a saturated NaHC03solution. The phases were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water, dried over anhydrous MgS04, filtered and concentrated. The crude product was purified by column chromatography or recrystallization to obtain compound P-5 as a solid.

[0724] General synthesis scheme XIV

[0725] For the first reaction step X = N-(C6-C 18 aryl)

[0726]

[0727] General procedure for synthesis:

[0728] AAV35: Stir E15 (1.10 eq), E16 (1.00 eq), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.01 eq), sodium tert-butoxide (NaOtBu, CAS: 865-48-5, 2.00 eq) and tri-tert-butylphosphine (P(tBu)3; CAS: 13716-12-6, 0.04 eq) in dry toluene at 60 °C under nitrogen atmosphere until the reaction is complete (TLC control). After cooling to room temperature (rt), extract the reaction mixture between ethyl acetate and brine and concentrate the combined organic layers under reduced pressure. Purify the crude material by column chromatography or by recrystallization to obtain E-5 as a solid.

[0729] AAV36: Stir E5 (1.00 eq), I-21 (1.00 eq), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.01 eq), sodium tert-butoxide (NaOtBu, CAS: 865-48-5, 2.00 eq) and tri-tert-butylphosphonium tetrafluoroborate (HP(t-Bu)3BF4; CAS: 131274-22-1, 0.02 eq) in dry toluene at reflux under nitrogen atmosphere until the reaction is complete (TLC control). After cooling to room temperature (rt), extract the reaction mixture between toluene and brine and concentrate the combined organic layers under reduced pressure. Purify the crude material by column chromatography or by recrystallization to obtain I-22 as a solid.

[0730] AAV37: Place I-22 (1.00 eq) in a round bottom flask under nitrogen. Add solvent 1,2-dichlorobenzene. Add boron tribromide (CAS: 10294-33-4, 3.00 eq) dropwise, heat it to 180 °C until the reaction is complete (TLC control). After cooling to rt, cool it further to 0 °C. Add DIPEA (CAS: 7087-68-5, 10.00 eq) and stir it for 1 h. Wash the reaction mixture with water and separate the phases, then remove the solvent under reduced pressure. Purify the crude material by column chromatography or by recrystallization to obtain P-8 as a solid.

[0731] General synthesis scheme XV

[0732]

[0733] General procedure for synthesis:

[0734] AAV38: E17 (1.40 eq), E18 (0.9 eq), hydroiodic acid (CAS: 10034-85-2, 0.20 eq) were stirred in dry acetonitrile at 100 °C under nitrogen atmosphere for 16 h. The reaction mixture was cooled to 0 °C; the precipitate was filtered and washed with cold acetonitrile. The solid was dissolved in acetonitrile; iodine (CAS: 7553-56-2, 0.40 eq) was added and the mixture was stirred at 100 °C until the reaction was complete (monitored by TLC). The reaction mixture was quenched with saturated sodium thio-sulfite solution and the precipitate was washed with cold acetonitrile, methanol and hexane. The crude material was purified by recrystallization or by column chromatography to obtain I-25 as a solid.

[0735] AAV39: I-25 (1.00 eq), E19 (6.0 eq), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.04 eq), tri-tert-butylphosphonium tetrafluoroborate (CAS: 131274-22-1, 0.16 eq) and sodium tert-butoxide (CAS: 865-48-5, 7.00 eq) were stirred in dry toluene at 110 °C for 72 h. After cooling to room temperature (rt), the reaction mixture was extracted between ethyl acetate and brine and the phases were separated and the solvent was removed under reduced pressure. The crude material was purified by recrystallization or by column chromatography to obtain I-26 as a solid.

[0736] AAV40: I-26 (1.00 eq) was taken in a round bottom flask under nitrogen. Solvent 1,2-dichlorobenzene was added. Boron tribromide (CAS: 10294-33-4, 4.00 eq) was added dropwise and heated to 180 °C until the reaction was complete (TLC control). After cooling to rt, it was further cooled to 0 °C. DIPEA (CAS: 7087-68-5, 10.00 eq) was added and stirred for 1 h. The reaction mixture was washed with water and the phases were separated and the solvent was removed under reduced pressure. The crude material was purified by column chromatography or recrystallization to obtain P-10 as a solid.

[0737] General synthesis scheme XVI

[0738]

[0739] General procedure for synthesis:

[0740] AAV41 : E17 (2.00 eq), E20 (1.0 eq) and bis(trifluoromethyl)methanol (CAS: 920-66-1, 300 mL) were stirred at room temperature under nitrogen atmosphere until the reaction was complete (TLC control). The reaction mixture was cooled to 0 °C; the precipitate was filtered and washed with cold acetonitrile. The solid was redissolved in acetonitrile; 1,4-benzoquinone (CAS: 106-51-4, 0.20 eq) was added and the mixture was stirred at room temperature until the reaction was complete (monitored by TLC). The solvent was removed under reduced pressure. The crude material was purified by recrystallization or by column chromatography to yield I-27 as a solid.

[0741] AAV42: I-27 (1.00 eq) and E21 (1.00 eq) were stirred in dichloromethane at room temperature under nitrogen atmosphere. Iodine (CAS: 7553-56-2, 0.03 eq) was added and the mixture was stirred at room temperature until the reaction was complete (monitored by TLC). The solvent was removed under reduced pressure. The crude material was purified by recrystallization or by column chromatography to yield I-28 as a solid.

[0742] AAV43: I-28 (1.00 eq), E19 (2.5 eq), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.03 eq), tri-tert-butylphosphonium tetrafluoroborate (CAS: 131274-22-1, 0.12 eq) and sodium tert-butoxide (CAS: 865-48-5, 4.00 eq) were stirred in anhydrous toluene at 110 °C until the reaction was complete (TLC control). After cooling to room temperature (rt), the reaction mixture was extracted between ethyl acetate and brine and the phases were separated and the solvent was removed under reduced pressure. The crude material was purified by recrystallization or by column chromatography to yield I-29 as a solid.

[0743] AAV44: I-29 (1.00 eq) was placed in a round bottom flask under nitrogen. Solvent chlorobenzene was added. Boron tribromide (CAS: 10294-33-4, 4.00 eq) was added dropwise and heated to 70 °C until the reaction was complete (TLC control). After cooling to rt, it was further cooled to 0 °C. DIPEA (CAS: 7087-68-5, 10.00 eq) was added and it was stirred for 1 hour. The reaction mixture was washed with water and the phases were separated, then the solvent was removed under reduced pressure. The crude material was purified by column chromatography or recrystallization to yield P-11 as a solid.

[0744] Preparation of E3

[0745]

[0746] General procedure for synthesis:

[0747] AAV45: E22 (1.00 equiv) was dissolved in anhydrous chloroform and N-bromosuccinimide (CAS: 128-08-5, 1.1 equiv) was added portionwise at 0 °C under a nitrogen atmosphere. The mixture was stirred at room temperature for 4 hours, then extracted between dichloromethane and water and the combined organic layers were concentrated under reduced pressure. The crude material was purified by column chromatography or by recrystallization to obtain E2 as a solid.

[0748] AAV46: E2 (1.00 equiv), bis(pinacolato)diboron (CAS: 73183-34-3, 1.5 equiv), [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(ll) (CAS: 72287-26-4, 0.02 equiv) and potassium acetate (KOAc; CAS: 127-08-2, 3.00 equiv) were stirred in anhydrous dioxane at 95 °C for 24 hours under a nitrogen atmosphere. After cooling to room temperature (rt), the reaction mixture was extracted between dichloromethane and water and the combined organic layers were concentrated under reduced pressure. The crude material was purified by column chromatography or by recrystallization to obtain E3 as a solid.

[0749] General synthesis scheme XVII

[0750]

[0751] General procedure for synthesis:

[0752] AAV47: E14 (1.00 equiv) was reacted with bis(pinacolato)diboron (1.50 equiv, CAS: 73183-34-3), potassium acetate (3.00 equiv, CAS: 127-08-2), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(ll) (0.04 equiv, CAS: 72287-26-4) in a mixture of anhydrous dioxane at 100 °C for 16 hours under nitrogen. After cooling to rt, water was added, the phases were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over anhydrous MgS04, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography or recrystallization to obtain compound 1-30 as a solid.

[0753] AAV48: Stir E2 (1.00 equiv), I-30 (1.00 equiv), [1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) (CAS: 72287-26-4, 0.02 equiv) and potassium phosphate tribasic (K3O4P; CAS: 7778-53-2, 3.00 equiv) in dioxane / water (4:1 by volume) at 80 °C under a nitrogen atmosphere for 4 h. After cooling to room temperature (rt), extract the reaction mixture between ethyl acetate and water and concentrate the combined organic layers under reduced pressure. Purify the crude material by column chromatography or by recrystallization to obtain I-21 as a solid.

[0754] The last two reaction steps were performed as described in AAV27 and AAV28.

[0755] General procedure for the synthesis:

[0756] AAV49: Stir E23 (1.00 equiv), E24 (1.15 equiv), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.01 equiv), sodium tert-butoxide (NaOtBu, CAS: 865-48-5, 3.20 equiv) and tri-tert-butylphosphonium tetrafluoroborate (HP(t-Bu)3BF4; CAS: 131274-22-1, 0.04 equiv) in dry toluene at 70 °C under a nitrogen atmosphere until the reaction is complete (TLC control). After cooling to room temperature (rt), extract the reaction mixture between ethyl acetate and brine and concentrate the combined organic layers under reduced pressure. Purify the crude material by column chromatography or by recrystallization to obtain E5a as a solid.

[0757] AAV50: React E14 (1.00 equiv) with bis(pinacolato)diboron (1.50 equiv, CAS: 73183-34-3), potassium acetate (3.00 equiv, CAS: 127-08-2), [1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) (0.04 equiv, CAS: 72287-26-4) in a mixture of dry dioxane under nitrogen at 100 °C for 16 h. After cooling to rt, add water, separate the phases and extract the aqueous layer with ethyl acetate. Dry the combined organic layers over anhydrous MgSO4, filter and concentrate under reduced pressure. Purify the crude product by column chromatography or recrystallization to obtain compound I-30 as a solid.

[0758] AAV51 : E2 (1.00 equiv), I-30 (1.00 equiv), [1,1 '-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) (CAS: 72287-26-4, 0.02 equiv) and potassium phosphate tribasic (K3O4P; CAS: 7778-53-2, 3.00 equiv) were stirred in dioxane / water (4:1 by volume) at 80 °C under nitrogen atmosphere for 4 h. After cooling to room temperature (rt), the reaction mixture was extracted between ethyl acetate and water and the combined organic layers were concentrated under reduced pressure. The crude material was purified by column chromatography or by recrystallization to yield I-21 as a solid.

[0759] AAV52: E5a (1.10 equiv), I-21 (1.00 equiv), tris(dibenzylideneacetone)dipalladium(0) (CAS: 51364-51-3, 0.02 equiv), sodium tert-butoxide (NaOtBu, CAS: 865-48-5, 3.20 equiv) and tri-tert-butylphosphonium tetrafluoroborate (HP(t-Bu)3BF4; CAS: 131274-22-1, 0.08 equiv) were stirred in anhydrous o-xylene at 120 °C under nitrogen atmosphere until the reaction was complete (TLC control). After cooling to room temperature (rt), the reaction mixture was extracted between ethyl acetate and brine and the combined organic layers were concentrated under reduced pressure. The crude material was purified by column chromatography or by recrystallization to yield I-31 as a solid.

[0760] AAV53: I-31 (1.00 equiv) was reacted with BBr3 (4.00 equiv, CAS: 10294-33-4) in anhydrous chlorobenzene at -10 °C for 3 h, at rt for 2 h, at 50 °C for 16 h and additionally at 70 °C for 2 h under nitrogen. After cooling to rt, DIPEA (10.0 equiv, CAS: 7087-68-5) was subsequently added to the mixture. Water was added, the phases were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water, dried over anhydrous MgS04, filtered and concentrated. The crude product was purified by column chromatography or recrystallization to yield compound P-12 as a solid.

[0761] Cyclic voltammetry

[0762] Cyclic voltammograms were measured by a solution of the organic molecule with a concentration of 10 -3 mol / L in dichloromethane or a suitable solvent and a suitable supporting electrolyte (e.g. 0.1 mol / L of tetrabutylammonium hexafluorophosphate). The measurements were performed at room temperature under nitrogen atmosphere using a three-electrode assembly (working electrode and counter electrode: Pt wire, reference electrode: Pt wire) and using FeCp2 / FeCp2 +Calibration as internal standard. Saturation Ag / AgCl electrode (SCE) was corrected for HOMO data using ferrocene as internal standard.

[0763] Density functional theory calculations

[0764] Molecular structures were optimized using the BP86 functional and the resolution of identity approach (RI). Excitation energies were calculated using the (BP86) optimized structures with the time-dependent DFT (TD-DFT) method. Orbital and excited state energies were calculated with the B3LYP functional. Def2-SVP basis set and m4 grid for numerical integration method were used. Turbomole step package was used for all calculations.

[0765] Photophysical measurements

[0766] Sample preparation: spin coating.

[0767] Instrument: Spin150, SPS euro.

[0768] Sample concentration was 10 mg / mL, dissolved in the appropriate solvent.

[0769] Procedure: 1) 3 seconds at 400 U / min. 2) 20 seconds at 1000 U / min with 1000 Upm / s. 3) 10 seconds at 4000 U / min with 1000 Upm / s. After coating, the film was dried at 70 °C for 1 min.

[0770] Photoluminescence spectra and time-correlated single-photon counting (TCSPC)

[0771] Steady-state emission spectra were measured from a Horiba Scientific Model l FluoroMax-4 equipped with a 150 W Xenon arc lamp, excitation and emission monochromators, and a Hamamatsu R928 photomultiplier tube and time-correlated single-photon counting option. Emission and excitation spectra were corrected using standard correction fits.

[0772] Excited state lifetimes were determined using the TCSPC method with the FM-2013 instrument and Horiba Yvon TCSPC hub using the same setup.

[0773] Excitation source:

[0774] NanoLED 370 (wavelength: 371 nm, pulse duration: 1.1 ns)

[0775] NanoLED 290 (wavelength: 294 nm, pulse duration: <1 ns)

[0776] SpectralLED 310 (wavelength: 314 nm)

[0777] Spectral LED 355 (wavelength: 355 nm).

[0778] Data analysis (exponential fit) was done using the software suite Data Station and DAS6 analysis software. The fit was assigned using the chi-squared test.

[0779] Photoluminescence quantum yield measurement

[0780] For photoluminescence quantum yield (PLQY) measurements, an absolute PL quantum yield measurement C9920-03G system (Hamamatsu Photonics) was used. The quantum yield and CIE coordinates were determined using the software U6039-05 version 3.6.0.

[0781] The emission maximum is given in nm, the quantum yield Φ in %, the CIE coordinates as x value, y value.

[0782] The PLQY was determined using the following protocol:

[0783] 1) Quality assurance: anthracene in ethanol (known concentration) was used as reference

[0784] 2) Excitation wavelength: the absorption maximum of the organic molecule was determined, the molecule was excited using this wavelength

[0785] 3) Measurement

[0786] For the samples, the quantum yield of the solution or film was measured under a nitrogen atmosphere. The yield was calculated using the equation:

[0787]

[0788] where n 光子 represents the photon count, Int. represents the intensity.

[0789] Manufacture and characterization of optoelectronic devices

[0790] The optoelectronic devices (such as OLED devices) comprising the organic molecules according to the application can be manufactured via vacuum deposition methods. If the layer comprises more than one compound, the weight percentage of one or more compounds is given in %. The total weight percentage value is 100%, so if no value is given, the fraction of this compound is equal to the difference between the given value and 100%.

[0791] The OLEDs, which are not fully optimized, are characterized using standard methods and measuring electroluminescence spectra, intensity dependent external quantum efficiency in % which is calculated using light detected by a photodiode and current. OLED device lifetime is extracted from changes in luminance during operation at constant current density. The LT50 value corresponds to the time at which the measured luminance decreases to 50% of the initial luminance, similarly, the LT80 corresponds to the point in time at which the measured luminance decreases to 80% of the initial luminance, the LT95 corresponds to the point in time at which the measured luminance decreases to 95% of the initial luminance, etc.

[0792] Accelerated lifetime measurements are performed (e.g., applying increased current density). For example, the LT80 value at 500 cd / m 2 is determined using the following equation:

[0793]

[0794] where L0represents the initial luminance at the applied current density.

[0795] The value corresponds to the average of several (typically two to eight) pixels, given the standard deviation between these pixels.

[0796] HPLC-MS:

[0797] HPLC-MS analysis is performed on an Agilent (1100 series) HPLC with MS detector (Thermo LTQ XL).

[0798] Exemplarily, a typical HPLC method is as follows: Agilent's reversed phase chromatography column 4.6 mm x 150 mm, particle size 3.5 μιη (ZORBAX Eclipse Plus C18, 4.6 x 150 mm, 3.5 μιη HPLC chromatography column) is used in the HPLC. The HPLC-MS measurement is performed at room temperature (rt) following a gradient.

[0799] Flow rate

[0800]

[0801] The following solvent mixtures are used:

[0802] Solvent A: [H2O (90%)] MeCN (10%) Solvent B: H2O (10%) MeCN (90%) Solvent C: THF (50%) MeCN (50%)

[0803] A sample injection of 5 μΐ^is taken from a solution with the analyte at a concentration of 0.5 mg / mL for the measurement.

[0804] The ionization of the probe was performed using an APCI (Atmospheric Pressure Chemical Ionization) source in positive (APCI+) or negative (APCI-) ionization mode.

[0805] Example 1

[0806]

[0807] Example 1 was synthesized according to the following steps:

[0808] AAV1 (84% yield),

[0809] AAV2 (45% yield),

[0810] AAV3 (32% yield).

[0811] MS (LC-MS): 586 m / z, at rt at: 5.73 min.

[0812] The emission maximum of Example 1 (2 wt% in PMMA) was at 428 nm with a full width at half maximum (FWHM) of 0.27 eV. The CIEx coordinate was 0.16 and the CIEy coordinate was 0.08. The photoluminescence quantum yield (PLQY) was 54%.

[0813] Example 2

[0814]

[0815] Example 2 was synthesized according to the general synthesis scheme VII:

[0816] AAV14 (33% yield), wherein 1,5-dibromo-2,3-dichlorobenzene (CAS: 81067-42-73) and 2,2'-dinaphthylamine (CAS: 532-18-3) were used as reactants E8 and E5, respectively,

[0817] AAV15 (34% yield), wherein 1 -(tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole (CAS: 1219637-88-3) was used as reactant E3,

[0818] AAV0-3 (3% yield).

[0819] MS (LC-MS, APCI ion source): 786.5 m / z, at rt at: 7.00 min.

[0820] The emission maximum of Example 2 (2 wt% in PMMA) was at 434 nm with a CIEx coordinate of 0.16 and a CIEy coordinate of 0.11.

[0821] Example 3

[0822]

[0823] Example 3 was synthesized according to general synthesis protocol III:

[0824] AAV4 (30% yield), wherein 5-bromo-N1,N1,N3,N3-tetraphenyl-1,3-benzenediamine (CAS: 1290039-73-4) was used as reactant E1,

[0825] AAV5 (21% yield), wherein 6-bromo-5H-benzo[f]furan-3-ylboronic acid (CAS: 1438427-35-0) was used as reactant E2,

[0826] AAV6 (4% yield).

[0827] MS (LC-MS, APCI source): 676.7 m / z, rt at: 6.87 min.

[0828] The emission maximum of Example 3 (2 wt% in PMMA) was at 440 nm with a full width at half maximum (FWHM) of 0.21 eV. The CIEx coordinate was 0.15 and the CIEy coordinate was 0.06. The photoluminescence quantum yield (PLQY) was 56%.

[0829] Example 4

[0830]

[0831] Example 4 was synthesized according to general synthesis protocol IV:

[0832] AAV7 (71% yield), wherein 1-(tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole (CAS: 1219637-88-3) and 3,5-dichloro-N,N-diphenylaniline (CAS: 1329428-05-8) were used as reactants E3 and E4, respectively,

[0833] AAV8 (52% yield), wherein N,N,N'-triphenyl-benzene-1,3-diamine (CAS: 1554227-26-7) was used as reactant E5,

[0834] AAV9 (3% yield).

[0835] MS (LC-MS, APCI source): 753.9 m / z, rt at: 6.62 min.

[0836] The emission maximum of Example 4 (2% by weight in PMMA) was at 427 nm with a full width at half maximum (FWHM) of 0.13 eV. The CIEx coordinate was 0.16 and the CIEy coordinate was 0.05. The photoluminescence quantum yield (PLQY) was 58%.

[0837] Example 5

[0838]

[0839] Example 5 was synthesized according to the general synthesis protocol V:

[0840] AAV10 (68% yield), wherein 2,2'-dinaphthylamine (CAS: 532-18-3) and 1-bromo-3- chlorodibenzo[b,d]furan (CAS: 2043962-13-4) were used as reactants E5 and E6, respectively,

[0841] AAV11 (90% yield), wherein 1-(tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole (CAS: 1219637-88-3) was used as reactant E3,

[0842] AAV9 (38% yield).

[0843] MS (LC-MS, APCI source): 609.5 m / z, at rt: 6.26 min.

[0844] The emission maximum of Example 5 (2% by weight in PMMA) was at 462 nm with a full width at half maximum (FWHM) of 0.14 eV. The CIEx coordinate was 0.14 and the CIEy coordinate was 0.22. The photoluminescence quantum yield (PLQY) was 65%.

[0845] Example 6

[0846]

[0847] Example 6 was synthesized according to the following procedure:

[0848] AAV7 (71% yield), wherein 1-(tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole (CAS: 1219637-88-3) and 3,5-dichloro-N,N-diphenylaniline (CAS: 1329428-05-8) were used as reactants E3 and E4, respectively,

[0849] AAV12 (54% yield), wherein N,N'-diphenylbenzidine (CAS: 5905-36-2) was used as reactant E7,

[0850] AAV13 (2% yield).

[0851] MS (LC-MS, APCI source) : 1094.1 m / z, rt at : 8.18 min.

[0852] The emission maximum of example 6 (2% by weight in PMMA) is at 443 nm with a full width at half maximum (FWHM) of 0.13 eV. The CIEx coordinate is 0.15 and the CIEy coordinate is 0.07. The photoluminescence quantum yield (PLQY) is 61%.

[0853] Example 7

[0854]

[0855] Example 7 was synthesized according to the following steps:

[0856] AAV16 (49% yield), wherein 1 -(tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole (CAS: 1219637-88-3) and 1,3-dibromo-2-chlorobenzene (CAS: 19230-27-4) were used as reactants E3 and E9, respectively,

[0857] AAV17 (78% yield),

[0858] AAV18 (56% yield), wherein 2,2'-dinaphthylamine (CAS: 532-18-3) was used as reactant E5,

[0859] AAV19 (69% yield),

[0860] AAV20 (5% yield).

[0861] MS (LC-MS, APCI source) : 519.6 m / z, rt at : 5.54 min.

[0862] The emission maximum of example 7 (2% by weight in PMMA) is at 480 nm with a full width at half maximum (FWHM) of 0.18 eV. The CIEx coordinate is 0.13 and the CIEy coordinate is 0.33. The photoluminescence quantum yield (PLQY) is 53%.

[0863] Example 8

[0864]

[0865] Example 8 was synthesized according to the following steps:

[0866] AAV21 (85% yield), wherein 1-bromo-2,5-dichloro-3-fluorobenzene (CAS: 202865-57-4) and 7H-dibenzo[c,g]carbazole (CAS: 194-59-2) were used as reactants E10 and E11, respectively;

[0867] AAV22 (62% yield), wherein 1-(tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole (CAS: 1219637-88-3) was used as substrate E3;

[0868] AAV23 (78% yield), wherein 2,4,6-trimethylphenylboronic acid (CAS: 5980-97-2) represents reactant E12;

[0869] and AAV0-3 (2% yield).

[0870] MS (LC-MS, APCI source): m / z = 635.7 at rt = 7.72 min.

[0871] The emission maximum of example 8 (2 wt% in PMMA) was at 470 nm with a full width at half maximum (FWHM) of 0.24 eV. The CIEx coordinate was 0.15 and the CIEy coordinate was 0.25. The photoluminescence quantum yield (PLQY) was 48%.

[0872] Example 9

[0873]

[0874] Example 9 was synthesized according to the following steps:

[0875] AAV24 (70% yield), wherein 1-bromo-2-chloro-3-fluorobenzene (CAS: 883499-24-9) and 7H-dibenzo[c,g]carbazole (CAS: 194-59-2) were used as reactants E13 and E11, respectively;

[0876] AAV25 (51% yield), wherein 1-(tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole (CAS: 1219637-88-3) was used as reactant E3;

[0877] and AAV0-3 (2% yield).

[0878] MS (LC-MS, APCI source): m / z = 517 at rt = 6.45 min.

[0879] The emission maximum of example 9 (2 wt% in PMMA) was at 478 nm with a full width at half maximum (FWHM) of 0.26 eV. The CIEx coordinate was 0.16 and the CIEy coordinate was 0.36. The photoluminescence quantum yield (PLQY) was 37%.

[0880] Example 10

[0881]

[0882] Example 10 was synthesized according to the following steps:

[0883] AAV21 (85% yield), wherein 1-bromo-2,5-dichloro-3-fluorobenzene (CAS: 202865-57-4) and 7H-dibenzo[c,g]carbazole (CAS: 194-59-2) were used as reactants E10 and E11, respectively;

[0884] AAV22 (62% yield), wherein 1-(tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole (CAS: 1219637-88-3) was used as substrate E3;

[0885] AAV23 (69% yield), wherein phenylboronic acid (CAS: 98-80-6) represented reactant E12;

[0886] and AAV0-3 (1% yield).

[0887] MS (LC-MS, APCI source): m / z = 593 at rt = 7.25 min.

[0888] The emission maximum of example 10 (2 wt% in PMMA) was at 485 nm.

[0889] Example 11

[0890]

[0891] Example 11 was synthesized according to the following steps:

[0892] AAV26 (34% yield), wherein 1-bromo-3-chlorodibenzo[b,d]furan (CAS: 2043962-13-4) and 1-(tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole (CAS: 1219637-88-3) were used as reactants E14 and E3;

[0893] AAV27 (37% yield), wherein 2,2'-dinaphthylamine (CAS: 532-18-3) was used as reactant E5;

[0894] and AAV28 (3% yield).

[0895] MS (LC-MS, APCI source): m / z = 609.5 at rt = 6.38 min.

[0896] The emission maximum of example 11 (2 wt% in PMMA) was at 456 nm with a full width at half maximum (FWHM) of 0.22 eV. The CIEx coordinate was 0.15 and the CIEy coordinate was 0.13. The photoluminescence quantum yield (PLQY) was 45%.

[0897] Example 12

[0898]

[0899] MS (LC-MS, APCI source): m / z = 1275.2 at rt = 8.99 min.

[0900] The emission maximum of example 12 (2 wt% in PMMA) was at 459 nm with a full width at half maximum (FWHM) of 0.15 eV. The CIEx coordinate was 0.14 and the CIEy coordinate was 0.13. The photoluminescence quantum yield (PLQY) was 53%.

[0901] Example 13

[0902]

[0903] Example 13 was synthesized according to the following steps:

[0904] AAV29 (71% yield), wherein 4-bromo-3-chlorodibenzo[b,d]furan (CAS: 1960445-63-9) and 2,2'-dinaphthylamine (CAS: 532-18-3) were used as reactants E14 and E5, respectively;

[0905] AAV30 (54% yield), wherein 1 -(tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole (CAS: 1219637-88-3) was used as compound E3;

[0906] and AAV31 (31% yield).

[0907] MS (LC-MS, APCI source): m / z = 609.7 at rt = 6.23 min.

[0908] The emission maximum of example 13 (2 wt% in PMMA) was at 464 nm with a full width at half maximum (FWHM) of 0.13 eV. The CIEx coordinate was 0.14 and the CIEy coordinate was 0.18. The photoluminescence quantum yield (PLQY) was 58%.

[0909] Example 14

[0910]

[0911] Example 14 was synthesized according to the following steps:

[0912] AAV32 (31% yield), wherein 3,6-bis(l,l-dimethylethyl)-l-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-9H-carbazole (CAS: 1510810-80-6) and 1,3-dibromo-5-tert- butyl-2-chlorobenzene (CAS: 1000578-25-5) were used as reactants E3 and E9, respectively;

[0913] AAV33 (48% yield), wherein N-[l,l'-biphenyl]-4-yl-[l,l'-biphenyl]-4-amine (CAS: 102113-98-4) was used as compound E5;

[0914] and AAV33 (24% yield).

[0915] MS (LC-MS, APCI ion source): m / z = 740.0 at rt = 7.90 min.

[0916] The emission maximum of Example 14 (2 wt% in PMMA) was at 440 nm with a full width at half maximum (FWHM) of 0.22 eV. The CIEx coordinate was 0.15 and the CIEy coordinate was 0.06. The photoluminescence quantum yield (PLQY) was 74%.

[0917] Example 15

[0918]

[0919] Example 15 was synthesized according to the following steps:

[0920] AAV38 (25% yield), wherein indole (CAS: 120-72-9) and 3,5-dibromobenzaldehyde (CAS: 56990-02-4) were used as reactants E17 and E18, respectively;

[0921] AAV39 (51% yield), wherein diphenylamine (CAS: 122-39-4) was used as E19;

[0922] and AAV40 (38% yield).

[0923] MS (LC-MS, APCI ion source): m / z = 1094.0 at rt = 8.14 min.

[0924] The emission maximum of example 15 (2 wt% in PMMA) was at 515 nm with a full width at half maximum (FWHM) of 0.13 eV. The CIEx coordinate was 0.31 and the CIEy coordinate was 0.64. The photoluminescence quantum yield (PLQY) was 31%.

[0925] Example 16

[0926]

[0927] Example 16 was synthesized according to the following steps:

[0928] AAV38 (25% yield), wherein indole (CAS: 120-72-9) and 3,5-dibromo- benzaldehyde (CAS: 56990-02-4) were used as reactants E17 and E18, respectively;

[0929] AAV39 (70% yield), wherein 2,2'-dinaphthylamine (CAS: 532-18-3) was used as E19;

[0930] and AAV40 (47% yield).

[0931] MS (LC-MS, APCI ion source): m / z = 1494.0 at rt = 8.74 min.

[0932] The emission maximum of example 16 (2 wt% in PMMA) was at 522 nm with a full width at half maximum (FWHM) of 0.09 eV. The photoluminescence quantum yield (PLQY) was 48%.

[0933] Example 17

[0934]

[0935] Example 17 was synthesized according to the following steps:

[0936] AAV41 (34% yield), wherein 4,7-dihydro-1 H-indole (CAS: 26686-10-2) and 3,5- dibromo-benzaldehyde (CAS: 56990-02-4) were used as reactants E17 and E20, respectively;

[0937] AAV42 (15% yield), wherein trimethyl orthoformate (CAS: 149-73-5) was used as E21 ;

[0938] AAV43 (19% yield), wherein bis(3-biphenyl)amine (CAS: 169224-65-1) was used as E19;

[0939] and AAV44 (27% yield).

[0940] MS (LC-MS, APCI ion source): m / z = 988.0 at rt = 8.56 min.

[0941] The emission maximum of example 17 (2 wt% in PMMA) was at 444 nm with a full width at half maximum (FWHM) of 0.29 eV. The CIEx coordinate was 0.15 and the CIEy coordinate was 0.09. The photoluminescence quantum yield (PLQY) was 45%.

[0942] Example 18

[0943]

[0944] Example 18 was synthesized according to the following steps:

[0945] AAV45 (85% yield), wherein 3,6-di-tert-butylcarbazole (CAS: 37500-95-1) was used as substrate E22;

[0946] AAV46 (83% yield);

[0947] AAV21 (85% yield), wherein 1-bromo-2,5-dichloro-3-fluorobenzene (CAS: 202865-57-4) and 7H-dibenzo[c,g]carbazole (CAS: 194-59-2) were used as reactants E10 and E11, respectively;

[0948] AAV22 (46% yield);

[0949] AAV23 (87% yield), wherein 2,4,6-trimethylphenylboronic acid (CAS: 5980-97-2) represents reactant E12;

[0950] and AAV0-3 (7.2% yield).

[0951] MS (LC-MS, APCI ion source): m / z = 746 at rt = 8.90 min.

[0952] The emission maximum of example 18 (2 wt% in PMMA) was at 471 nm with a full width at half maximum (FWHM) of 0.24 eV. The CIEx coordinate was 0.14 and the CIEy coordinate was 0.25. The photoluminescence quantum yield (PLQY) was 48%.

[0953] Example 19

[0954]

[0955] Example 19 was synthesized according to the following steps:

[0956] AAV47 (74% yield), wherein 4-bromo-2-chlorodibenzo[b,d]furan (CAS: 2087889-86-7) was used as substrate E14;

[0957] AAV45 (85% yield), wherein 3,6-di-tert-butylcarbazole (CAS: 37500-95-1) was used as substrate E22;

[0958] AAV48 (74% yield);

[0959] AAV27 (33% yield), wherein bis(4-tert-butylphenyl)amine (CAS: 4627-22-9) was used as compound E5;

[0960] and AAV28 (6.1% yield).

[0961] MS (LC-MS, APCI source): m / z = 734.8 at rt = 8.73 min.

[0962] The emission maximum of example 19 (2 wt% in PMMA) was at 471 nm with a full width at half maximum (FWHM) of 0.16 eV. The CIEx coordinate was 0.13 and the CIEy coordinate was 0.26. The photoluminescence quantum yield (PLQY) was 76%.

[0963] Example D1

[0964] Example 5 was tested in OLED D1 which was fabricated with the following layer structure:

[0965] Layer No. Thickness D1 9 100 nm Al 8 2 nm Liq 7 11 nm NBPhen 6 20 nm MAT1 5 20 nm MAT2 (98%): Example 5 (2%) 4 10 nm MAT3 3 50 nm MAT4 2 7 nm HAT-CN 1 50 nm ITO Substrate Glass

[0966]

[0967] OLED D1 produced an external quantum efficiency (EQE) of 8.7% at 1000 cd / m 2 The emission maximum was at 466 nm with a FWHM of 18 nm at 3.9 V. The corresponding CIEx value was 0.13 and the CIEy value was 0.16. The LT95 value was determined to be 55.2 h at 1200 cd / m 2

[0968] Additional examples of inventive organic molecules / oligomers

[0969]

[0970]

[0971]

[0972] ​

[0973]

[0974]

[0975]

[0976]

[0977]

[0978]

[0979]

[0980]

[0981]

[0982]

[0983]

[0984]

[0985]

[0986]

[0987]

[0988]

[0989]

[0990]

[0991]

[0992]

[0993]

[0994]

[0995]

[0996]

[0997]

[0998]

[0999] Ph = phenyl

[1000]

[1001] Ph = phenyl

[1002]

[1003]

[1004]

[1005]

[1006]

[1007]

[1008]

[1009]

[1010]

[1011]

[1012]

[1013]

[1014]

[1015]

[1016]

[1017]

[1018]

[1019]

[1020]

[1021]

[1022]

[1023]

[1024]

[1025]

[1026]

Claims

1. An organic molecule comprising a structure having a plurality of units, wherein, each unit comprises a structure represented by Formula IV: wherein, m is 2, n＝1； X is, at each occurrence, NR 3 ; R 1 , R 2 , and R IV are independently at each occurrence selected from the group consisting of hydrogen; deuterium; CF3; CN; halogen; and C1-C6alkyl, optionally substituted with one or more substituents R 5 ; R 3 independently at each occurrence is: C6-Ci8-aryl, optionally substituted with one or more substituents R 18 independently at each occurrence is: C6-Ci8-aryl, optionally substituted with one or more substituents R 5 independently at each occurrence is: C6-Ci8-aryl, optionally substituted with one or more substituents R R I independently at each occurrence is selected from the group consisting of hydrogen; deuterium; CF3; CN; halogen; C1-C6alkyl, optionally substituted with one or more substituents R 5 ; and C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; R II and R III is independently at each occurrence selected from the group consisting of hydrogen; deuterium; CF3; CN; halogen; C1-C6alkyl optionally substituted with one or more substituents R 5 ; C2-C6alkenyl optionally substituted with one or more substituents R 5 ; and C2-C6alkynyl optionally substituted with one or more substituents R 5 ; R V independently at each occurrence is N(C6-C 18 aryl)2; R a independently at each occurrence is selected from the group consisting of hydrogen; deuterium; OR 5 ; CF3; CN; halogen; C1-C6alkyl, optionally substituted with one or more substituents R 5 ; C2-C6alkenyl, optionally substituted with one or more substituents R 5 ; C2-C6alkynyl, optionally substituted with one or more substituents R 5 ; and C6-C 18 aryl, optionally substituted with one or more substituents R 5 ; R 5 at each occurrence, is independently selected from the group consisting of: hydrogen; deuterium; CF3; CN; F; Br; and I; wherein the substituents R a Optionally, a benzene ring or benzofuran ring is formed, and R d and R e are combined with each other to form an aromatic six-membered ring; wherein the groups R II and R III optionally combine with each other to form an aromatic six-membered ring, which is optionally substituted with one or more C1-C5alkyl, deuterium, halogen, CN, or CF3, and wherein, two units each represented by Formula IV are fused together by sharing ring a or sharing ring c or both ring b and ring c; and wherein, if ring b and ring c of one unit represented by Formula IV are shared by ring b and ring c of an adjacent unit represented by Formula IV, the direct bond between ring b and ring c can also be shared.

2. The organic molecule according to claim 1, comprising a structure selected from the group consisting of:

3. The organic molecule according to claim 1, comprising structures of Formula IVa-0 and Formula IVb-0:

4. The organic molecule according to claim 1 or 3, comprising a structure of Formula IVb-0b:

5. The organic molecule according to any of claims 1 to 3, wherein R 1 and R 2 are independently hydrogen or deuterium, R 3 is C6-C 18 aryl, R I is hydrogen, deuterium or C6-C 18 aryl, R II , R III and R IV are independently hydrogen or deuterium, and R 5 is hydrogen or deuterium.

6. The organic molecule according to any of claims 1 to 3, wherein R a at each occurrence is: hydrogen; deuterium; OR 5 ; and C6-C 18 aryl, optionally substituted with one or more substituents R 5 .

7. An organic molecule selected from the following compounds:

8. An optoelectronic device comprising an organic molecule according to any one of claims 1 to 6 or claim 7 as light-emitting emitter.

9. The optoelectronic device according to claim 8, being an organic light-emitting diode.

10. A composition comprising: (a) an organic molecule according to any one of claims 1 to 6 or claim 7, in the form of an emitter and / or a host; and (b) an emitter and / or host material different from the organic molecule; and (c) optionally, a dye and / or a solvent.

11. An optoelectronic device comprising an organic molecule according to any one of claims 1 to 6 or claim 7 or a composition according to claim 10, in the form of an organic light-emitting diode.

12. The optoelectronic device according to claim 11, comprising: a substrate; an anode; and a cathode, wherein the anode or the cathode is disposed on the substrate; and a light-emitting layer disposed between the anode and the cathode and comprising the organic molecule or the composition.

13. A method for fabricating an optoelectronic device, wherein, The method using an organic molecule according to any one of claims 1 to 6 or claim 7 or a composition according to claim 10, comprises the step of processing the organic molecule by vacuum evaporation or from solution.

Images